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ABSTRACT
Purpose: To compare baseline CVD risk factor profiles among groups of individuals with
discordant levels of high- and low-density lipoprotein cholesterol (HDL-C and LDL-C
respectively) compared to lipoprotein particle concentration

(HDL-P

and LDL-P

respectively) and examine the associations between lipoprotein discordance and incident
type 2 diabetes mellitus (T2D) and metabolic syndrome (MetS). Furthermore, to examine
the association between lipoprotein discordance and exercise induced changes in CVD risk
factors.
Methods: Standard lipid panels as well as lipoprotein subclass profiles via nuclear
magnetic resonance spectroscopy were measured among three previously completed
studies (CARDIA cohort, HERITAGE Family Study, and HART-D study) spanning over
4,000 male and female participants. 1) Aerobic training only (AT), 2) Resistance training
only (RT), 3) Combined AT/RT. Four exclusive HDL and LDL discordance groups were
created based on baseline median lipoprotein cholesterol/particle concentrations as
follows: 1) low/low (< median for both cholesterol and particle), 2) low/high (< median
cholesterol, ≥ median particle), 3) high/low, and 4) high/high. Cross-sectional associations
between baseline discordance group and CVD risk factors were assessed via multivariable
linear regression. Continuous discordance levels were created by subtracting individual
particle percentile ranking from cholesterol percentile ranking (e.g. HDL-C – HDL-P). The
association between continuous lipoprotein discordance and cross-sectional CVD risk
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factors was assessed correlational analysis, while the association of incident T2D or MetS
with lipoprotein discordance was assessed via multivariable proportional hazards
regression. The relationship between lipoprotein discordance and exercise induced changes
in CVD risk factors was assessed via multivariable linear regression.
Results: Cross sectional analyses revealed that for HDL discordance, more favorable risk
profiles (e.g. lower BMI, larger mean HDL-P and LDL-P size) were associated with higher
HDL-C, while in LDL discordance groups more favorable risk factors were associated with
lower LDL-P. In women only, both HDL and LDL discordance were associated with T2D
and MetS risk with higher risk being associated with lower HDL-C and higher LDL-P.
Associations of lipoprotein discordance with exercise induced changes in CVD risk factors
were primarily limited to lipoprotein specific variables (e.g. HDL discordance significantly
associated with changes in mean HDL-P size).
Conclusions: Lipoprotein discordance is associated with cross-sectional differences in
CVD risk factors with more favorable risk factor profiles being found in those with high
HDL-C

and

low

LDL-P

regardless

of

discordance

status.

Lipoprotein

concordant/discordant status is also a significant risk factor for both T2D and MetS in
women only, although racial disparities may be present. Furthermore, lipoprotein
discordance status is primarily associated with exercise training induced changes in
lipoprotein subclass measures. Thus, while lipoprotein discordance is minimally predictive
of exercise training responses outside of lipoprotein subclass measures, our findings
support the regular measurement of lipoprotein particle concentrations alongside of
cholesterol measures in chronic disease management and prevention.
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CHAPTER 1
INTRODUCTION

Cholesterol levels of both low-density (LDL-C) and high-density (HDL-C)
lipoproteins have been regularly associated with cardiovascular disease (CVD) risk. A
large body of evidence supports a positive association between LDL-C and CVD 1-3, while
HDL-C levels display an inverse relationship with CVD.3-6 Collective data from 26
randomized trials supports intensive LDL-C lowering as a means to reducing CVD risk.7
Many patients with well controlled LDL-C, however, still have considerable residual CVD
risk, with an average of nine percent of treated patients from prospective studies of optimal
statin therapy still experiencing major CVD events.8 Low HDL-C levels are largely
supported in epidemiological literature as a risk factor for CVD, however, randomized
controlled trials with niacin or inhibitors of cholesterol ester transfer protein have not
improved CVD outcomes despite significant increases in HDL-C levels.9-12 Thus,
cholesterol content may not fully capture the risk associated with these lipoprotein
particles.
Both LDL and HDL are largely heterogeneous lipoproteins, varying in size,
density, composition and function. Advanced techniques such as nuclear magnetic
resonance (NMR) and vertical auto profile are able to provide subclass measurements of
these lipoproteins, revealing their diversity and offering alternative measures to cholesterol
content in estimating CVD risk. One popular alternative to cholesterol content is measuring
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the concentration of both LDL and HDL particles (LDL-P and HDL-P respectively). While
both LDL-C and HDL-C measure the amount of cholesterol bound to these particles, LDLP and HDL-P represent the number of respective particles carrying this cholesterol load.
When comparing LDL-P to LDL-C, total LDL-P has been shown to have stronger
associations with both subclinical disease13 and CVD events14,

15

than LDL-C, with

increased LDL-P levels associated with higher risk. Similarly, analysis from the MultiEthnic Study of Atherosclerosis (MESA) found total HDL-P to have an independent,
inverse association with coronary heart disease (CHD) and subclinical disease, while HDLC was not significantly associated when both HDL-P and HDL-C were included in the
model.16 Conventional analyses like these use both cholesterol content and particle
concentration separately in statistical models to predict risk, thus treating them as
independent predictors. However, both LDL-C and HDL-C are not biologically
independent of their particle concentrations and treating them as such may not account for
the biological similarities represented by each variable.
One way to account for both the biological similarities and differences represented
by cholesterol content and particle concentration is lipoprotein discordance analysis.
Lipoprotein discordance analyses have traditionally used standardized lipoprotein
cholesterol concentrations and made ratios of these numbers with standardized lipoprotein
particle concentration or a non-cholesterol variant (e.g., LDL-C/LDL-P). From this ratio,
a level of concordance/discordance can be derived, representing the relative similarity
between an individual’s cholesterol and particle concentration measures. This similarity is
gauged by ranking an individual’s cholesterol and particle concentrations amongst their
respective study population. Individuals are deemed concordant if their rankings for both
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metrics are relatively close and/or identical to each other. On the other hand, if the ranking
for one metric is considerably different than the other, than this person would be deemed
discordant. Discordance status (i.e. being concordant or discordant) is then used to estimate
risk for subclinical and clinical CVD.
Many studies have examined the association of LDL discordance (LDL-C/LDL-P)
on cardiovascular risk15, 17-23, with only one study also examining the association of HDLC/HDL-P discordance with CVD risk.17 The general consensus regarding LDL is that in
concordant groups, both LDL-C and LDL-P equally predict risk. In the case of discordant
LDL-C/LDL-P, risk of adverse cardiovascular outcomes tracks more so with LDL-P, with
increased LDL-P levels indicating higher risk.18, 19 In the single study examining HDL
discordance, discordance between HDL-P and HDL-C (percentage difference) was not a
significant predictor of incident CHD or CVD events in three separate groups of
participants (metabolic syndrome without diabetes, diabetes mellitus, neither metabolic
syndrome nor diabetes mellitus), however, in the entire sample, higher levels of HDL
discordance (higher HDL-P and lower HDL-C) were associated with lower CHD and CVD
risk.17 While much of the literature on lipoprotein discordance focuses on clinical and
subclinical indices of CVD, no studies have examined the longitudinal associations of
either LDL or HDL discordance with incident metabolic syndrome (MetS) or type 2
diabetes (T2D), important risk factors for CVD.
Exercise is well known to improve the lipoprotein profile, including increases in
HDL-C and large HDL-P concentrations, along with decreases in small LDL-P
concentration and increases in LDL particle size.24,
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However, the effects of regular

exercise on LDL and HDL discordance is unknown, as well as how baseline discordance
status is associated with exercise induced changes in CVD risk factors.
Therefore, the present study proposes to analyze the cross-sectional and
longitudinal associations of LDL and HDL discordance with CVD risk factors and risk of
MetS and T2D in the Coronary Artery Risk Development in Young Adults (CARDIA)
Study cohort study (N=3891). Additionally, we intend to examine the effect of baseline
discordance status on changes in multiple CVD risk factors in two exercise intervention
studies: the HEalth, RIsk factors, exercise Training And GEnetics (HERITAGE) Family
Study (N=715) and the Health Benefits of Aerobic and Resistance Training in individuals
with type 2 diabetes (HART-D) study (N=214). These goals will be addressed through the
following aims.
Aims 1 and 2
Aim 1 will evaluate the cross-sectional relationship between LDL and HDL
discordance status and multiple cardiovascular risk factors (resting blood pressure [BP],
fasting blood glucose [FBG], fasting insulin, C-reactive protein levels [CRP], physical
activity levels [PA], cardiorespiratory fitness [CRF], and multiple NMR based lipoprotein
subclass traits).
Aim 2 will examine the association between discordance status and incident T2D,
or incident MetS over 23 years of follow. Both aims will analyze data from the CARDIA
Study.
For both aims, Year 7 data from the CARDIA study will be used to classify LDL
and HDL based lipoprotein discordance status via two methods: 1) Median based
discordance, 2) Continuous discordance

3

For median based discordance, separate categorical discordance groups will be
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater
than or equal to the race- and sex-specific median value as high and below the median as
low. Four exclusive cholesterol/particle discordant groups will be made for both LDL and
HDL from these base categories: 1) low/low (below the median for both cholesterol content
and particle concentration), 2) low/high (below the median for cholesterol content, at or
above the median for particle concentration), 3) high/low (at or above the median for
cholesterol content, below the median for particle concentration), and 4) high/high (at or
above the median for both cholesterol content and particle concentration).
Lipoprotein cholesterol and particle concentrations will be rank ordered into raceand sex-specific percentiles to establish continuous discordance status. Continuous
discordance will then be defined by subtracting an individual’s lipoprotein particle
percentile from their lipoprotein cholesterol percentile. Race- and sex-specific quartiles of
continuous discordance will also be created and tested.
Aim 1 Objectives
Objective 1: Examine the relationship between a) median based lipoprotein discordance,
b) continuous lipoprotein discordance levels and multiple cross-sectional cardiovascular
risk factors.
Hypothesis 1a: Those in the discordant group with low levels of LDL-C and high LDL-P
will have the worst CVD risk factor profile relative to other LDL discordant/concordant
groups. These participants will have the highest BP, fasting insulin, FBG, and CRP. This
group will also have lower PA levels, CRF, and CVH. Those with the highest levels of
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both HDL-C and HDL-P will have the most favorable CVD risk profile relative to other
HDL discordant groups.
Hypothesis 1b: Participants with the lower continuous LDL discordance levels (indicating
LDL-P percentages higher than LDL-C percentages) will have worse CVD risk factor
profiles. Participants with higher continuous HDL discordance levels (indicating HDL-P
percentages lower than HDL-C percentages) will have worse CVD risk factor profiles.
Aim 2 Objectives
Objective 2: Assess the risk of incident T2D or MetS associated with baseline a) median
based lipoprotein discordance, and b) continuous lipoprotein discordance levels
Hypothesis 2a: Those in the discordant group with low levels of LDL-C and high LDL-P
will have the highest risk of T2D or MetS relative to other LDL discordant/concordant
groups. Those with the highest levels of both HDL-C and HDL-P will have the lowest risk
of T2D or MetS relative to other HDL discordant/concordant groups.
Hypothesis 2b: Lower continuous LDL discordance levels (indicating LDL-P percentages
higher than LDL-C percentages) will be associated with higher risk for T2D or MetS.
Higher continuous HDL discordance levels (indicating HDL-P percentages lower than
HDL-C percentages) will be associated with lower risk of T2D or MetS.
Aim 3
Aim 3 will examine the association of baseline LDL or HDL discordance status
with exercise induced changes in multiple cardiovascular risk factors (BP, BMI, body fat
percentage, FBG, fasting insulin, inflammatory markers, CRF, hepatic lipase, lipoprotein
lipase, and NMR lipoprotein subclass profiles). These relationships will be analyzed in
participants from the HERITAGE Family study and the HART-D study.

5

Baseline LDL and HDL based lipoprotein discordance will be classified via two
methods: 1) Median based discordance and 2) Continuous discordance as previously
described above in aims 1 and 2. Post intervention discordance will also be classified via
continuous discordance.
Aim 3 Objectives
Objective 3.1: Examine the relationship between baseline a) median based lipoprotein
discordance (HERITAGE), and b) continuous lipoprotein discordance levels (HART-D)
and exercise induced changes in CVD risk factors.
Hypothesis 3.1a: Those in the discordant group with low levels of LDL-C and high LDLP will experience the largest improvements in CVD risk factors relative to other LDL
discordant/concordant groups. Also, those with the lowest levels of both HDL-C and HDLP (concordantly low HDL) will experience the largest improvements in CVD risk factors
relative to other HDL discordant/concordant groups.
Hypothesis 3.1b: Continuous LDL discordance levels will be inversely associated with
improvements in CVD risk factors. Those who have lower LDL discordance levels
(indicating LDL-P percentages higher than LDL-C percentages) will see increased benefit
of exercise relative to higher LDL discordance levels. Continuous HDL discordance levels
will be positively associated with improvements in CVD risk factors. Those who have
higher HDL discordance levels (indicating HDL-C percentages higher than HDL-P
percentages) will experience increased benefit of exercise relative to lower HDL
discordance levels.
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Objective 3.2: Examine whether exercise induced changes in continuous lipoprotein
discordance differs between baseline median based lipoprotein discordance groups
(HERITAGE)
Hypothesis 3.2: Those in the discordant group with low levels of LDL-C and high LDLP will experience the largest improvements in continuous lipoprotein discordance levels,
becoming

more

concordant

with

lower

LDL-P,

relative

to

other

LDL

discordant/concordant groups. Also, those in the discordant group with the low HDL-C and
high HDL-P will experience the largest improvements in continuous lipoprotein
discordance levels, becoming more concordant with increased HDL-C, relative to other
HDL discordant groups.
These studies will likely be the first to examine the longitudinal relationship
between lipoprotein cholesterol/particle discordance and either T2D or MetS. While
studies have found cross sectional associations between lipoprotein discordance and both
T2D and MetS18, 22, none have examined if discordant conditions manifest before the onset
of either T2D or MetS. Similarly, we will be the first to examine the relationship between
HDL discordance and either condition.
Furthermore, no studies have explored the association between lipoprotein
discordance and exercise induced changes in CVD risk factor profiles. Assessment of this
relationship may provide valuable information for the prescription of exercise as a
treatment or preventive measure for CVD and other related chronic conditions.
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CHAPTER 2
LITERATURE REVIEW
LDL, HDL and CVD Risk
Both LDL-C and HDL-C have been thoroughly investigated as major contributors
to atherogenesis and CVD. Numerous studies show that LDL-C and HDL-C are among the
strongest, independent risk factors for CVD, with LDL-C being positively associated and
HDL-C being inversely associated with CVD risk.1-6, 26, 27 Collective data of over 170,000
participants from 26 randomized statin treatment trials reveals a 22% reduction in one year
risk of major vascular event per mmol/L (38.67 mg/dL) reduction of LDL-C.7
Nevertheless, an average of 9% of treated patients from prospective studies of optimal
statin therapy still experience major CVD events, representing a considerable residual risk.8
Analysis from the Framingham study showed a 2.5% lower 12 year CHD risk per mg/dL
of HDL-C at baseline. Clinical trials aimed at increasing HDL-C levels, however, have not
improved CVD outcomes despite significant increases in HDL-C.9-12 These findings have
led to the investigation of alternative lipoprotein measurements as cholesterol content alone
may not fully encompass LDL and HDL related disease risk.
Both LDL and HDL are largely heterogeneous particles varying in size, density,
and composition. The advent of NMR and other lipoprotein subclass analyses have allowed
for incorporation of these alternative lipoprotein traits in chronic disease risk assessment.
One popular risk assessment alternative to cholesterol is lipoprotein particle concentration.
Lipoprotein particle concentration represents the respective number of LDL or HDL
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particles present, while cholesterol content is representative of the amount of cholesterol
carried by these particles. When comparing particle and cholesterol indices, total LDL-P
has been shown to have stronger associations with both subclinical disease13 and CVD
events14, 15 than LDL-C, with increased LDL-P levels associated with higher risk. Analysis
from the Framingham Offspring Study shows a 28% increased risk of incident CVD (HR
1.28, 95% CI 1.18 to 1.40) per standard deviation (SD) increase in LDL-P, while each SD
increment in LDL-C was only associated with an 11% risk increase over a median follow
up of 14.8 years.15 Furthermore, among the placebo arm of the Jupiter trial, baseline LDLP (HR 1.21 per standard deviation [SD] higher, 95% CI 1.07 to 1.37) and not LDL-C (HR
1.03, 95% CI 0.88 to 1.21) was associated with incident CVD events over a 1.9 year median
follow up.28 Similar analysis from the MESA cohort compared quartiles of HDL-C and
HDL-P in predicting risk of incident CHD over a mean of 6 years follow up.16 In comparing
the highest quartile to the lowest, the authors found total HDL-P (HR 0.49, 95% CI 0.27 to
0.86), but not HDL-C (HR 0.92, 95% CI (0.48 to 1.77), to have an independent inverse
association with coronary heart disease (CHD) and subclinical disease, when both HDL-P
and HDL-C were included in the model.16 Analyses like these that use both cholesterol
content and particle concentration in risk prediction separately in statistical models, treat
them as independent predictors. However, because both LDL-C and HDL-C are not
biologically independent of their particle concentrations, treating cholesterol content and
particle concentration as independent predictors does not account for both the biological
similarities represented by each variable.29
As opposed to treating cholesterol content and particle concentration as
independent predictors of risk, recent literature has employed lipoprotein discordance
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analysis to account for both the biological similarities and differences represented by each
variable. Lipoprotein discordance analyses generally use standardized lipoprotein
cholesterol concentrations and compare them to another lipoprotein metric such as particle
concentration (e.g., LDL-C/LDL-P). From this ratio, a level of concordance/discordance
can be derived, representing the relative similarity between an individual’s cholesterol and
particle concentration measures. This similarity is gauged by ranking individuals within a
study cohort by their cholesterol levels and particle concentrations separately. Individuals
are deemed concordant if their rankings for both metrics are relatively close and/or
identical to each other. Conversely, if the ranking for one metric is considerably different
than the other, than this person would be deemed discordant. Discordance status (i.e. being
concordant or discordant) is then used to estimate risk for adverse outcomes of concern.
For the intents and purposes of this review, the focus was literature examining
discordance between cholesterol content and particle concentration (or a particle
concentration surrogate) of both LDL and HDL. Several studies examining LDL based
discordance have used apoB as their particle concentration measure while others have used
direct measurement of LDL-P from methods such as NMR analysis or vertical auto profile
testing. ApoB is the primary protein constituent of atherogenic lipoproteins which consist
of chylomicron remnants, very low density lipoproteins, intermediate density lipoproteins,
LDL, and lipoprotein(a).30 ApoB is present in these lipoproteins at one molecule per
particle, thus being an indicator for particle concentration. Because the large majority of
apoB molecules reside within LDL particles (generally over 90%), apoB and LDL-P
concentrations may generally be treated as operationally equivalent.31 In the case of HDL,
the primary protein on these particles, apoA-1, is present in varied amounts per particle.
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Thus, apoA-1 is not as reliable an estimate of HDL-P concentration as apoB is for LDL-P
and direct measurements of HDL-P are more appropriate.
Methods of Defining Lipoprotein Discordance
Of the studies examining discordance between lipoprotein cholesterol content and
particle concentration, there are multiple methods used to define discordance. The methods
employed in the literature on LDL or HDL cholesterol/particle discordance include:
Median based, percentile based (continuous or categorical), residual based, and quartile
based.
Median Based Discordance.
Median based discordance studies establish high and low groups of both cholesterol
content and particle concentration based upon the median value in the study population.
Separate categorical discordance groups are created by denoting LDL-C, LDL-P, HDL-C,
and HDL-P values greater than or equal to median value as high and below the median as
low. Four particle/cholesterol groups are then made via these classifications 1) low/low
(below the median for both particle concentration and cholesterol content), 2) low/high
(below the median for particle concentration, at or above the median for cholesterol
content), 3) high/low (at or above the median for particle concentration, below the median
for cholesterol content), and 4) high/high (at or above the median for both particle
concentration and cholesterol content).
In an analysis of the Framingham offspring cohort, Cromwell et al. (2007) found
that 21% of those with low LDL-C were discordant with high levels of LDL-P. Over a
median follow up of 14.8 years, this discordant group (high LDL-P/low LDL-C) had an
increased CVD event rate (85 per 1000 person years) relative to the group with low LDL-
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C and LDL-P levels (65 per 1000 person years), thus showing that regardless of LDL-C
levels, high LDL-P is associated with increased CVD risk. 15
Similar median based analysis from the Women’s Health Study examined
discordance between LDL-C and both apoB and LDL-P.19 In this study, 19% of
participants were discordant with either high or low apoB compared to LDL-C, while 24%
were discordant for LDL-P relative to LDL-C. Discordant groups with either low apoB or
LDL-P were found to have the lowest prevalence of smokers, diabetics, or hypertensives.
Furthermore, these groups had lower mean BMI and CRP levels. Among groups with
discordantly high apoB (high apoB/low LDL-C) or LDL-P (high LDL-P/low LDL-C),
CHD event risk over 18 years was higher than concordantly low groups (hazard ratio [HR]
2.98, 95% confidence interval [CI] 2.41 to 3.68, p < 0.0001 for apoB; HR 2.68, 95% CI
2.18 to 3.30, p <0.0001 for LDL-P). Opposingly, in discordant groups with low apoB (low
apoB/high LDL-C) or LDL-P (low LDL-P/high LDL-C), CHD event risk was lower than
concordantly high group (HR 0.31, 95% CI 0.23 to 0.41, p <0.0001 for apoB; HR 0.39,
95% CI 0.31 to 0.48, p <0.0001 for LDL-P).19 The authors conclude that, in women with
discordant LDL measures, CHD risk may be underestimated or overestimated if LDL-C
alone is used. 19 Therefore, people with discordantly low LDL particle metrics (low LDLP/high LDL-C) would have their risk overestimated by LDL-C while CHD risk for those
with discordantly high LDL particle metrics (high LDL-P/low LDL-C) would be
underestimated.
Wilkins et al. (2016) examined the development of coronary artery calcification
(CAC) among LDL discordant groups in the CARDIA cohort. 18 % of participants were
found to be discordant between apoB and LDL-C.17 At baseline, the group with
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discordantly high apoB had multiple CVD risk factors within normal limits (waist
circumference, BMI, total cholesterol, LDL-C, non-HDL-C, triglycerides, HDL-C). Over
25 years of follow up, the group with discordantly high apoB (high apoB/low LDL-C) were
at increased odds of CAC (Odds ratio 1.55, 95% CI 1.10 to 2.18, p <0.01) relative to the
concordantly low group (low apoB/low LDL-C). Additionally, those with discordantly low
apoB (low apoB/high LDL-C) did not have increased odds of CAC (Odds ratio 1.29, 95%
CI 0.91 to 1.83) when compared to the concordantly low group, showing that CAC odds
may follow LDL-P levels as opposed to LDL-C.20
Percentile Based Discordance.
Percentile-based discordance can be used in a continuous or categorical manner. In
the case of continuous percentage-based discordance, both the lipoprotein concentrations
and cholesterol content of the study sample are rank ordered into percentages. The
difference in percentage between particle concentration and cholesterol content is then used
as a continuous variable to predict outcomes. Alternatively, studies have determined a
specific cutoff percentage difference that is deemed as discordant. In this case three
categorical groups are made with one concordant group, another discordant with particle
concentration being higher than cholesterol content, and a second discordant group where
particle concentration is less than that of cholesterol content.
Otvos et al (2011) examined the association of percentile based (categorical)
discordance in the MESA cohort with cross sectional carotid intima media thickness as
well as incident CVD events. The authors chose a cutoff of ±12 % difference between
LDL-P and LDL-C to be classified as discordant. This difference was chosen to assure that
50 % of the population tested was classified as discordant (25% with LDL-P > LDL-C and
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25% with LDL-P < LDL-C). The discordant group with LDL-P > LDL-C had a higher
proportion of metabolic syndrome, obese, Hispanics, and males relative to the concordant
group. This same group also had the lowest mean LDL particle size and highest carotid
intima media thickness. Cox regression analysis revealed that, among discordant groups,
LDL-P (HR 1.41, 95% CI 1.15 to 1.75, p = 0.001) and not LDL-C (HR 1.17, 95% CI 0.96
to 1.42, p = 0.13) was a significant predictor of incident CVD events over a mean follow
up of 5.5 years.18
In the only study on adolescents, Mietus-Snyder et al. (2013) examined cross
sectional CVD risk factor profiles amongst groups of sixth grade students in the
HEALTHY primary prevention trial with discordant levels of LDL-P relative to LDL-C.
Categorical percentage-based discordance was used with a cutoff of ± 20 % difference
between LDL-P and LDL-C to classify discordance. This cutoff produced a 34 % overall
discordance rate. No difference in fasting glucose was found between groups, however, the
discordant group with LDL-P > LDL-C had significantly higher insulin and HOMA-IR
levels relative to concordant and LDL-P < LDL-C groups (Bonferroni P ≤0.05 between all
groups). The same LDL-P > LDL-C group also had worse CVD risk factor profiles outside
of insulin resistance. This group had increased mean BMI, triglycerides, very large density
lipoprotein particle concentration, and lower HDL-C and HDL-P levels compared to both
other groups (Bonferroni P ≤0.05 between all groups).21 This study highlights that
discordant phenotypes and their associated risk factors may begin to manifest early in life.
Tehrani

et

al.

(2016),

similar

to

Otvos,

also

examined

lipoprotein

cholesterol/particle discordance in the MESA cohort, however groups were further
categorized by metabolic syndrome status. Continuous percentile-based discordance
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analysis was performed on the entire study population for both HDL and LDL, after which
participants were separated into one of three groups: 1) MetS without T2D, 2) T2D, or 3)
Neither MetS nor T2D. Mean LDL percent discordance differed between diseased and nondiseased groups, however MetS and T2D groups did not differ. Mean HDL discordance
percent was significantly different between all groups. Investigations into the association
between lipoprotein discordance and incident CHD or CVD events revealed that higher
levels of LDL discordance (increased LDL-P and decreased LDL-C) were associated with
increased risk of both CHD (HR, 1.21 95% CI 1.01 to 1.47, p <0.05) and CVD (HR 1.26,
95% CI 1..07 to 1.47, p <0.05) in the MetS group only. HDL discordance was not predictive
of either CHD or CVD in any of the study groups, however, in the entire sample, higher
levels of HDL discordance (increased HDL-P and decreased HDL-C) were associated with
lower CHD (HR 0.90, 95% CI 0.81 to 1.00, p <0.05) and CVD (HR 0.90, 95% CI 0.83 to
0.99, p <0.05) events.17 Findings from this study highlight that the association between
lipoprotein discordance with CVD may differ by chronic disease status.
Residual Based Discordance.
Residual based discordance uses linear regression to predict particle concentration
based on cholesterol content. Discordance status is then based on the difference in true
particle concentration versus expected concentration from regression analysis.
Pencina et al. (2015) examined the association of residual based discordance and
incident CHD in the Framingham Offspring cohort over 20 years of follow up. Expected
apoB concentrations based on LDL-C were expressed via linear regression. The difference
between measured and expected apoB was calculated, separated into tertiles and used in
Cox regression models to investigate the relationship between apoB discordance and risk
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of CHD. In the third tertile, where apoB was higher than expected, there were more men
and participants were older with decreased HDL-C and increased BMI and triglycerides
relative to lower tertiles. Furthermore, this group had increased proportions of
hypertensives and metabolic syndrome. Cox regression analysis revealed that the lowest
tertile (apoB lower than expected) was at lower risk of CHD (HR 0.70, 95% CI 0.51 to
0.96), while the highest tertile was at an increased risk (HR 1.46, 95% CI 1.14 to 1.86)
relative to the middle tertile (apoB ≈ expected).22 Similar to other studies on LDL
discordance, Pencina et al. (2015) show that lower LDL particle concentrations, as
represented by apoB, are associated with more favorable outcomes relative to high
concentrations.
Quintile Based Discordance.
Quintile based discordance separates both cholesterol content and particle
concentrations of study participants into quintiles. Having a particle concentration quintile
a set amount away (1 quintile or more) from the same persons cholesterol quintile is
deemed as being discordant.
Analysis from the Quebec Cardiovascular Study examined the association between
quintile based apoB/LDL-C discordance and coronary artery disease (CAD) risk.
Participants were separated into quintiles based on both apoB and LDL-C separately.
Discordance was classified as having a quintile for apoB that was one or more quintiles
different than that of LDL-C. This method produced a 51% discordance rate between apoB
and LDL-C. Discordantly high apoB (apoB quintile > LDL-C quintile) was associated with
increased BMI and triglycerides as well as lower HDL-C and LDL-P size relative to those
discordantly low for apoB (apoB quintile < LDL-C quintile). Cox proportional hazard
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models compared two discordant groups (apoB > LDL-C and apoB < LDL-C) to the group
of participants concordant in quintile one (lowest apoB and LDL-C levels). Both the
discordantly high and discordantly low apoB groups were found to be at an increased 5
year risk for CAD with a hazard ratio of 3.2 (95% CI 1.2 to 8.1, p = 0.02) for discordantly
high apoB and 3.0 (95% CI 1.1 to 7.8, p = 0.03) for discordantly low apoB.23 Findings from
this study suggest that having both low apoB and low LDL-C may be ideal for minimizing
LDL related CAD risk.
Conclusion
The general consensus from the literature is that higher levels of apoB or LDL-P
are associated with increased risk of CVD. Cross sectionally, increased apoB or LDL-P
levels are associated with adverse CVD risk factor profiles. These risk factor differences
have been found as early as adolescence, where those with LDL-P > LDL-C showed
increased insulin resistance and BMI among other factors.21 Median based analysis from
the Women’s Health Study shows that in discordant groups, CVD risk tends to track with
particle indices rather than cholesterol content.19 Thus, someone with high levels of LDLC but low levels of LDL-P may be at lower risk for future CVD events than their LDL-C
would reflect. This is somewhat supported by data from the CARDIA study where those
discordantly low for apoB (low apoB/high LDL-C) did not have increased odds of CAC
when compared to the concordantly low group (low apoB / low LDL-C).20
When it comes to HDL discordance, only one study investigated the association between
HDL-P / HDL-C discordance and CVD events using data from the MESA cohort.
Participants were broken into three groups based on metabolic syndrome status and
continuous HDL discordance levels were not predictive of future CVD events in any of the
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groups. However, in combined analysis, increased levels of HDL discordance (higher
HDL-P / lower HDL-C) was associated with lower CVD risk. Clearly, further research on
HDL discordance and CVD is needed to form a general consensus.
Literature Limitations
While much of the literature on discordance between particle indices and
cholesterol content focuses on CVD risk or cross-sectional risk factor profiles, none have
examined the longitudinal associations between these conditions and MetS or T2D.
Because both MetS and T2D are widely accepted risk factors for CVD it may be important
to know if lipoprotein imbalances between particle indices and cholesterol content manifest
before these chronic conditions. Furthermore, the literature on HDL-P / HDL-C
discordance and chronic disease is sparse.
Exercise also plays a considerable role in CVD risk and the progression of CVD
risk factors. Multiple studies support exercise as a preventive measure, aiding in achieving
more favorable CVD risk profiles and lower levels of chronic diseases, however, no prior
studies have examined how discordance between lipoprotein particles and their cholesterol
content may affect exercise induced changes in CVD risk factors.
Thus, the present study proposes to analyze the cross sectional and longitudinal
associations of LDL and HDL discordance with CVD risk factors and risk of MetS and
T2D in CARDIA Study cohort. Additionally, we intend to examine the effect of baseline
discordance status on changes in multiple CVD risk factors in two exercise intervention
studies: the HERITAGE Family Study and the HART-D study. Findings from this study
may inform future treatment for MetS and T2D as well as influence exercise prescription
for people with discordant lipoprotein metrics
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CHAPTER 3
GENERAL METHODOLOGY
Aims 1 and 2
Aim 1 will evaluate the cross-sectional relationship between LDL and HDL
discordance status and multiple cardiovascular risk factors (BP, FBG, CRP levels, PA
levels [exercise units], CRF, and AHA’s Life’s Simple Seven metric). Aim 2 will examine
the association between discordance status and incident type 2 diabetes, or incident
metabolic syndrome over 23 years of follow up. Both aims will analyze data from the
CARDIA Study.
Study Design
The CARDIA study is a multicenter prospective cohort of 5115 black and white
men and women examining the determinants of clinical and sub-clinical CVD. Participants
aged 18-30 at baseline (year 0) were recruited from four regions in the United States:
Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota and Oakland,
California. Enrollment at each site was balanced by sex, age (18-24 vs. 25-30), race, and
education. Follow up was performed at years 2, 5, 7, 10, 15, 20, 25, and 30 with retention
rates of 90%, 86%, 81%, 77%, 74%, 72%, 72%, and 71%, respectively. Our analysis
employed data from years 7 to 30 of the study. Additional details on design and recruitment
for the study have been previously published.32 Approval from institutional review boards
was obtained annual by each field, and participants provided informed consent at each
exam
19

Measurements
Standardized protocols were used at each center across all examinations.
Participants were asked to fast for at least 12 h before each examination and avoid smoking
or heavy physical activity (PA) at least 2 h prior.
Anthropometrics. Height and weight were measured at each examination while
wearing no shoes and light examination clothing. Height was measured via vertical ruler
to the nearest 0.5 cm and weight to the nearest 0.2 kg with a calibrated balance beam scale.
BMI was calculated as weight in kg divided by height in meters squared.
Blood pressure was measured by trained technicians after participants had rested for 5
minutes using and random zero sphygmomanometer (years 7 through 20). Year 25 and 30
blood pressure was measured using an Omron digital blood pressure monitor. All pressures
were measured in triplicate with the average of the final two measurements used for
analysis.
Fasting blood draws were taken according to standard protocol.32 Total cholesterol
was measured via enzymatic assay. Glucose was measured via hexokinase coupled to
glucose-6-phosphate dehydrogenase.
Smoking status was acquired via self-report.
Type 2 Diabetes Classification. Diabetes status at each exam was classified as a
fasting glucose >7.0 mmol/l (126 mg/dl) or the use of oral hypoglycemic medications or
insulin. Diabetic status was assessed in every exam from year 7 to 30.
Metabolic Syndrome Classification. Metabolic syndrome status at each exam was
defined as ≥ 3 of the following: (1) waist circumference >88 cm (35 in) for women and
>102 cm (40 in) for men, (2) HDL-C <1.0 mmol/L (40 mg/dl) for men or <1.3 mmol/L (50
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mg/dl) for women, (3) fasting triglycerides ≥ 1.7 mmol/L (150 mg/dl), (4) blood pressure
(BP) ≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or on treatment, or (5) fasting glucose
of 5.6 to 7.0 mmol/L (100 to 125 mg/dl). Participants reporting use of medications for
diabetes or hypertension were also classified as having met the criterion for elevated
glucose or blood pressure, respectively. Metabolic syndrome status was assessed in every
exam from year 7 to 30.
High Sensitivity C-Reactive Protein (hs-CRP). Fasting plasma samples from
year 7 exam were used to measure hs-CRP via a Roche latex-particle enhanced
immunoturbidimetric assay kit. Assays were read via Roche Modular P Chemistry
analyzer. Assay range for hs-CRP was 0.175 to 1100 μg/ml.33 Elevated hs-CRP was
classified as a concentration greater than 3.0 mg/L.
Cardiorespiratory Fitness (CRF). Cardiorespiratory fitness was measured via
maximal graded treadmill testing using a modified Balke protocol at years 0, 7, and 20.34,
35

CRF was defined as time in minutes that participants were able to walk or run on the

treadmill. Race and sex specific CRF quartiles were established.
Nuclear Magnetic Resonance (NMR) Lipoprotein Profiles. Lipoprotein profile
analysis was performed on year 7 plasma samples via NMR spectroscopy at Liposcience,
Inc. (Raleigh, NC) using the LipoProfile-3 algorithm.36 Each measurement provides
information on lipoprotein particle concentrations such as large, medium, and small very
low density lipoprotein (VLDL-P) and HDL-P, large and small LDL-P, and intermediate
density lipoprotein (IDL-P). Total VLDL-P, LDL-P, and HDL-P concentrations were
calculated by adding together their respective subclass concentrations with IDL-P factoring
into the overall LDL-P concentration. The weighted average particle diameter for each
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lipoprotein is calculated as the sum of the lipoprotein subclass diameters multiplied by its
relative mass percentage as estimated from the amplitude of its methyl NMR signal.
Parity and Gestational Diabetes Mellitus (GDM). At each examination women
were asked if they had diabetes and if they had diabetes only during pregnancy (GDM).
Parity was also assessed at each examination and was defined as a live birth of >20 weeks’
gestation.
Lipoprotein Discordance Classification. Year 7 data will be used to classify LDL
and HDL based lipoprotein discordance via three methods: 1) Median based discordance,
2) Continuous discordance, and 3) Quartiles of continuous discordance.
For median based discordance, separate categorical discordance groups will be
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater
than or equal to the sex-specific median value as high and below the median as low. Four
exclusive cholesterol/particle discordant groups will be made for both LDL and HDL from
these base categories: 1) low/low (below the median for both cholesterol content and
particle concentration), 2) low/high (below the median for cholesterol content, at or above
the median for particle concentration), 3) high/low (at or above the median for cholesterol
content, below the median for particle concentration), and 4) high/high (at or above the
median for both cholesterol content and particle concentration).
Lipoprotein cholesterol and particle concentrations will be rank ordered into sex
specific percentiles to establish continuous discordance status. Continuous discordance
will then be defined by subtracting an individual’s lipoprotein particle percentile from their
lipoprotein cholesterol percentile.
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Statistical Analysis
Aim 1. The cross-sectional association between LDL and HDL discordance status
and CVD risk factors at year 7 will be assessed via multivariable linear and logistic
regression. Separate models for median based discordance, continuous discordance, and
quartiles of discordance will be assessed. All models will be adjusted for age, race, sex,
BMI (except in CVH and BMI models), center, smoking status and statin usage. Linear
regression will be used for the outcomes of moderate to vigorous PA (MVPA) level, CRF,
BMI, blood pressure, hs-CRP, fasting glucose, and CVH.
Aim 2. The longitudinal association between year 7 LDL and HDL discordance
status with incident T2D and MetS over 23 years of follow up will be assessed via Cox
proportional hazard regression. Three separate discordance models will be examined with
LDL or HDL discordance as independent variables: 1) median based discordance, 2)
continuous discordance, and 3) quartiles of continuous discordance. All sex specific
models will be adjusted for race, and the time varying covariates of age, smoking, statin
usage, and BMI. Age and race interactions with discordance will also be examined.
Aim 3
Aim three will examine the effect of baseline LDL or HDL discordance on exercise
induced changes in multiple cardiovascular risk factors (BP, BMI, body fat percentage,
FBG, fasting insulin, CRP, CRF, hepatic lipase, lipoprotein lipase, glycA, and NMR
lipoprotein profiles). These relationships will be analyzed in participants from the
HERITAGE Family Study and the HART-D study.
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Study Design: HERITAGE Family Study
Full details of the design and methods of the HERITAGE Family Study have been
previously reported.37 Briefly, the HERITAGE Family Study included 715 black (34%),
and white men and women (55%) aged 17-65 years. Participants were sedentary at baseline
with a BMI less than 40 kg/m2 and normotensive to mildly hypertensive (<160/100
mmHg). Each participant completed a 20-week exercise intervention which consisted of
three exercise sessions per week on a cycle ergometer. Exercise sessions started at 30
minutes at the heart rate associated with 55% VO2max for the first two weeks and progressed
to a target of 50 minutes at 75% of VO2max for each session, which was maintained for the
final six weeks of training.37
Measurements
Anthropometrics. Height and weight were measured in duplicate to the nearest 0.1
cm and 0.1 kg, respectively, using a stadiometer and balance beam scale. A third
measurement was taken if the first two measurements differed by more than 0.5 cm for
height or 200 g for weight. BMI was then calculated as weight divided by height in meters
squared.
Resting BP was measured using the Colin STBP-780 automated BP unit (San
Antonio, TX) after a 5-minute rest period. Four measurements were taken with resting BP
being reported as the mean of three or more reliable measurements.
Blood Samples. Blood samples were collected from an antecubital vein into
vacutainer tubes containing EDTA. Samples were taken in the morning after a 12 hour fast
with subjects in a supine position. Samples were taken twice at baseline and 24 and 72
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hours after the last exercise training session. For women, samples were obtained early in
the follicular phase of the menstrual cycle.
Lipids and Lipoproteins. Plasma very low-density lipoproteins (VLDL) were
isolated via ultracentrifugation. HDL fractions were obtained after precipitation of LDL in
the infranatant by the heparin-manganese chloride method. Total cholesterol and
triglyceride levels were determined in plasma and lipoproteins via enzymatic methods
(Technicon RA- 500 Analyzer; Bayer Corporation Inc., Tarrytown, NY).
Fasting Glucose and Insulin. An intravenous glucose tolerance test was
administered in the morning after an overnight fast. Blood samples were collected through
a venous catheter from an antecubital vein to determine plasma glucose and insulin. Plasma
glucose was measured enzymatically38, while plasma insulin was measured via
radioimmunoassay with polyethylene glycol separation.39
Lipoprotein Lipase and Hepatic Lipase. Plasma lipoprotein lipase (LPL) and
hepatic lipase (HL) were measured after a 12-hour overnight fast and 10 minutes after
intravenous injection of heparin (60 IU/kg body weight). Post heparin lipase activities were
measured as previously described.40 Lipolytic enzyme activities were expressed as
nanomoles of oleic acid released per milliliter of plasma per minute.
High Sensitivity C-Reactive Protein (hs-CRP). Plasma hs-CRP was measured at
baseline and after the 20-week exercise training program via a high-sensitivity solid-phase
chemiluminescent immunometric assay (IMMULITE 2000 High Sensitivity CRP,
Diagnostic Products Corporation, Los Angeles, CA) implemented on an automated
immunoassay instrument (Diagnostic Products Corporation, Los Angeles, CA). In a
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sample of 48 blind duplicates, the intra-class correlation was 0.98 and the coefficient of
variation was 6.4%.41
Lipoprotein Subclass Profiles and GlycA. Comprehensive lipoprotein profiling
and GlycA analysis was performed on baseline and post-training plasma samples via NMR
spectroscopy at Liposcience, Inc. (Raleigh, NC) using the LipoProfile-3 algorithm.36 Each
profile measurement provides information on lipoprotein particle concentrations such as
large, medium, and small very low density lipoprotein (VLDL-P) and HDL-P, large and
small LDL-P, and intermediate density lipoprotein (IDL-P). NMR signal amplitudes
originating from the N-acetyl methyl group protons of N-acetylglucosamine residues on
the glycan branches of glycoproteins were used to quantify GlycA concentrations. GlycA
in a systemic inflammatory marker that has been associated with incident CVD,
independent of traditional risk factors.42-46
Maximal Oxygen Consumption (VO2max). VO2max was measured via two
maximal exercise tests, on separate days before and after the 20-wk training program. Tests
were administered via a cycle ergometer (model 800S, SensorMedics, Yorba Linda, CA)
connected to a metabolic cart (model 2900, SensorMedics). An electrocardiogram machine
was used to monitor heart rate. During each exercise stage, gas exchange variables (O2
uptake, CO2 output, minute ventilation, and respiratory exchange ratio) were recorded as a
rolling average of three 20-s intervals. The criteria for VO2max were as follows: respiratory
exchange ratio >1.1, plateau in O2 uptake (change of <100 ml/min in the last 3 consecutive
20-s averages), and a heart rate within 10 beats/min of the maximal level predicted by age.
All subjects achieved at least one of the VO2max criteria before and after training. The
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majority of the exercise tests were conducted at the same time of day, with at least 48 h
between tests.
To adjust for differential body sizes and fitness levels, the initial power output for
the first maximal test was 40–50 watts for 3 minutes followed by increases of 10–25 watts
at 2-minute intervals until volitional exhaustion. During the second maximal test, subjects
exercised for 8 – 12 minutes at 50 watts, 8–12 minutes at 60% VO2max, and 3 minutes at
80% VO2max. In the case that 50 watts was >60% VO2max, the power output associated with
60% was done first followed by 50 watts. The resistance was then increased to the highest
power output attained in the first maximal test. If subjects were able to pedal after 2
minutes, power output was increased every 2 minutes thereafter until volitional fatigue.
The average VO2max from these two tests was taken as the VO2max for that subject if both
values were within 5% of each other. If they differed by more than 5%, the higher VO2max
value was then used. Reproducibility of VO2max in these subjects was examined and
characterized by an intraclass correlation coefficient of 0.97 for repeated tests with a
coefficient of variation of 5%.47
Body Composition Measurements. Body density and body fat percentage were
determined by underwater weighing.48 Reproducibility of the body density, fat mass, and
pulmonary residual volume measurements was high, with intraclass correlation
coefficients between 0.97 and 1.00. There were no differences in reproducibility among
the four clinical centers.48 Visceral adipose tissue was measured using computed axial
tomography at the level of the intervertebral disc between lumbar vertebrae 4 and 5.49
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Study Design: HART-D Study
The HART-D study included 214 sedentary (54.7% White, 40.6% Black, 3.7%
Asian, 0.5% Hispanic, 0.5% Other) men and women (63.6%) aged 30 – 75 years with type
2 diabetes and HbA1c levels of 6.5% to 11.0%. Participants had a BMI less than 48 kg/m2,
blood pressure below 160/100 mm Hg, fasting triglycerides below 500 mg/dL, urine
protein less than 100 mg/dL and serum creatinine under 1.5 mg/dL. Further exclusion
criteria included use of an insulin pump, history of stroke, advanced neuropathy or
retinopathy, or any serious medical condition that prevented participants from adhering to
the protocol or exercising safely.
HART-D was a nine-month exercise intervention with a control group and three
exercise training groups: aerobic exercise training only (AT), resistance exercise training
only (RT), and a combination of aerobic and resistance training (AT/RT). The non-exercise
control group was asked to maintain their normal level of activity during the 9 months and
were offered weekly stretching and relaxation classes.
The AT group exercised three to five days/week at an intensity of 50–80% of their
VO2max for a total dose of 12 kcal/kg/week. Caloric expenditure was adjusted weekly based
upon weight changes. American College of Sports Medicine equations were used to
calculate caloric expenditure and therefore time required per exercise session.
The RT group trained 3 days/week. Each session included two sets of four upper
body exercises (chest press, lateral pull-down, military press, and seated row), three sets of
three lower body exercises (leg press, leg ex- tension, and hamstring curl), and two core
exercises (abdominal crunches and back extensions). Each set consisted of 10-12
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repetitions. The prescribed weight was increased when participants could complete 12
repetitions on the last set of each exercise for two consecutive sessions.
The AT/RT group was prescribed 3 days/week of aerobic exercise at a dose of 10
kcal/kg/week and 2 resistance training sessions per week. Resistance exercises and their
progression were the same as those in the resistance training only group, however, only
one set of each exercise was performed.
Measurements
All measurements were taken at baseline and at one of two follow up visits. Follow
up visit one occurred between 48 and 96 hours following the final exercise session.
Similarly, the second follow up visit occurred between 48 and 96 hours following follow
up visit one.
Anthropometrics. Height was measured via a standard stadiometer and weight
was measured on a GSE 450 electronic scale (GSE Scale Systems, Novi, Michigan). BMI
was calculated as weight in kg divided by height in meters squared.
Blood Samples. Blood samples were collected via venipuncture after a minimum
10-hr fast. Post intervention samples were collected within 48 to 96 hours of the final
exercise bout.
Lipids and Lipoproteins. Fasting blood lipids (total cholesterol, LDL-C, HDL-C,
and triglycerides) were analyzed on a DXC 600 Pro (Beckman Coulter Inc, Brea,
California).
Fasting Glucose and Insulin. Glucose was measured on a DXC 600 Pro (Beckman
Coulter Inc, Brea, California). Insulin was measured via immunoassay on a Siemens 2000
(Siemens, Deerfield, Illinois).
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High Sensitivity C-Reactive Protein (hs-CRP). Plasma hs-CRP at baseline and
post intervention was measured using a solid phase chemiluminescent immunometric assay
on Immulite 2000 analyzer (Siemens, Deerfield, Illinois) Samples were stored at −80 C°
and analyzed at the conclusion of the HART-D trial.
Body Composition Measurements. Body composition was measured via dualenergy x-ray absorptiometry scans performed on a QDR 4500A whole-body scanner
(Hologic Inc, Bed- ford, Massachusetts).
Lipoprotein Subclass Profiles and GlycA. Comprehensive lipoprotein profiling
and GlycA analysis was performed on baseline and post-training plasma samples via NMR
spectroscopy at Labcorp, Inc. (Morrisville, NC) using the LipoProfile-4 algorithm.36 Each
profile measurement provides information on lipoprotein particle concentrations such as
very large, large, medium, small and very small triglyceride rich lipoprotein and large,
medium, and small HDL-P and LDL-P. NMR signal amplitudes originating from the Nacetyl methyl group protons of N-acetylglucosamine residues on the glycan branches of
glycoproteins were used to quantify GlycA concentrations.
Maximal Oxygen Consumption (VO2max). VO2max was measured via maximal
exercise tests conducted on a treadmill (Trackmaster 425, Carefusion, Newton, Kansas)
with respiratory gases sampled through a True Max 2400 Metabolic Measurement Cart
(ParvoMedics, Salt Lake City, Utah). A modified Balke protocol was used for the maximal
test. Participants self-selected a walking pace and the grade increased by 2% every two
minutes until exhaustion. The same speed was used for baseline and post-intervention
testing.
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Lipoprotein Discordance Classification. Baseline LDL and HDL based
lipoprotein discordance for both studies will be classified via two methods as previously
described: 1) Median based discordance and 2) Continuous discordance. Post intervention
discordance was also classified via continuous discordance.
Statistical Analysis
The association of baseline median based (HERITAGE) or continuous
(HERITAGE and HART-D) LDL and HDL discordance status with exercise induced
changes in CVD risk factors will be assessed via multivariable linear regression. Base
models will be adjusted for age, race, sex, BMI and statin usage. Full models will
additionally be adjusted for baseline trait (i.e. adjusting for baseline BMI when assessing
for changes in BMI). HART-D models will additionally be adjusted for training group
assignment with the interaction between discordance and group assignment also being
explored.
The association of baseline median based (HERITAGE) or continuous (HART-D)
LDL and HDL discordance status with exercise induced changes in continuous discordance
status will also be assessed via multivariable linear regression. Base models will be
adjusted for age, race, sex, BMI and statin usage. Baseline LDL discordance status will be
used to predict changes in continuous LDL discordance while baseline HDL discordance
status will be used to predict changes in continuous HDL discordance. HART-D models
will additionally be adjusted for training group assignment with the interaction between
discordance and group assignment also being explored.
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CHAPTER 4
ASSOCIATION OF DISCORDANCE BETWEEN LOW-DENSITY LIPOPROTEIN AND
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL VERSUS PARTICLE
CONCENTRATION WITH THE PREDICTION OF TYPE 2 DIABETES AND
METABOLIC SYNDROME

Abstract
Purpose: To compare cardiovascular disease (CVD) risk factor profiles among groups of
individuals with and without discordant levels of high and low-density lipoprotein
cholesterol (HDL-C and LDL-P respectively) compared to particle concentration (HDL-P
and LDL-P respectively) and examine the associations between lipoprotein discordance
status and incident type 2 diabetes mellitus (T2D) and metabolic syndrome (MetS).
Methods: All included phenotypes were measured at the year seven exam among 3891
participants of the CARDIA study. Sex-specific median-based lipoprotein discordance
groups were created and combined into four exclusive cholesterol/particle groups for both
HDL and LDL. Continuous discordance levels were created by subtracting individual
particle percentile ranking from cholesterol percentile ranking (e.g. HDL-C – HDL-P).
Cross-sectional associations between both median based and continuous discordance with
baseline CVD risk factors were assessed via multivariable linear regression and partial
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correlation, respectively. The association of incident T2D or MetS with lipoprotein
discordance was assessed via multivariable proportional hazards regression.
Results: Cross sectional analyses (both median and continuous) revealed that more
favorable risk profiles (e.g. lower BMI, larger mean HDL-P, and LDL-P size) were found
in high HDL-C groups regardless of discordance status. However, overall, discordantly
high HDL-C (/Low HDL-P) groups displayed the most favorable profiles. Concordantly
Low median based LDL groups displayed the most favorable risk profiles, while
continuous LDL discordance was most strongly associated with LDL subclass measures
(r=0.51 for mean LDL-P size; r=-0.50 for small LDL-P concentration; p<0.0001 for both).
In women only, both HDL and LDL discordance were associated with T2D and MetS risk,
with higher risk being associated with lower HDL-C (Low HDL-C/High HDL-P at highest
risk of T2D) and higher LDL-P (Low LDL-C/High LDL-P at highest risk of MetS). Race
specific associations were found for median based LDL discordance with T2D risk (Black
women only) and continuous HDL discordance with MetS risk (Whites only).
Conclusions: Lipoprotein discordance is associated with differences in CVD risk factor
profiles, with more favorable risk factor profiles generally being found in those with high
HDL-C or low LDL-P. Lipoprotein concordant/discordant status is a significant risk
factor for both T2D and MetS in women only, although racial disparities may be present.
These data support the regular measurement of lipoprotein particle concentrations
alongside of cholesterol measures in chronic disease management and prevention.
Introduction
A large body of evidence supports a positive association between low-density
lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD) 1-3, while high-density
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lipoprotein cholesterol (HDL-C) levels are inversely related with CVD.3-6 However, Many
patients with well controlled LDL-C still have considerable residual CVD risk.8
Furthermore, randomized controlled trials with niacin or inhibitors of cholesterol ester
transfer protein have not improved CVD outcomes despite significant increases in HDL-C
levels.9-12 Both LDL and HDL are largely heterogeneous lipoproteins varying in size,
composition, density, and function. Thus, their attributable risk may not be solely
represented by their cholesterol content.
Novel techniques such as nuclear magnetic resonance (NMR) spectroscopy can
provide measurements of lipoprotein subclasses, which may provide more insight into
potential biomarkers underlying the CVD risk associated with these particles. Total particle
concentrations of both LDL and HDL (LDL-P and HDL-P respectively) have been shown
to be independent risk factors for CVD, often outperforming their respective cholesterol
contents in risk estimation.14-16 These analyses treat cholesterol content and particle
concentration of the respective lipoproteins as separate independent predictors, however,
this does not account for the biological similarities represented by each variable.29
The concept of lipoprotein discordance accounts for the biological similarities and
differences between cholesterol content and particle concentration by creating a ratio of
the two measures in each respective lipoprotein (e.g. LDL-C/LDL-P). Individuals within a
study cohort are ranked separately by their cholesterol content and particle concentrations
and a level of concordance/discordance is derived, representing the relative similarity of
their rankings for each metric. Multiple studies have evaluated LDL discordance (LDLC/LDL-P) based CVD risk15, 17-23 with the general consensus that both LDL-C and LDL-P
equally predict outcomes in concordant groups (e.g. high LDL-C/high LDL-P). However,
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in the case of discordant LDL-C/LDL-P (e.g., high LDL-C/low LDL-P), risk tracks more
so with LDL-P, with higher LDL-P levels indicating higher risk. 18, 19 Limited literature on
HDL discordance points to higher levels of HDL discordance (higher HDL-P and lower
HDL-C) being associated with higher CVD risk although the relationship may be
confounded by chronic disease status such as type 2 diabetes (T2D) or metabolic syndrome
(MetS).17 While the body of literature on lipoprotein discordance primarily focuses on
clinical and subclinical indices of CVD, no studies have examined the longitudinal
associations of either LDL or HDL discordance with incident metabolic syndrome (MetS)
or type 2 diabetes (T2D), important risk factors for CVD.50
Therefore, the purpose of the present study was to analyze cross-sectional CVD
risk factor profiles and longitudinal associations of LDL and HDL discordance with risk
of MetS and T2D in the Coronary Artery Risk Development in Young Adults (CARDIA)
Study cohort study.
Methods
Study Design
The CARDIA study is a multicenter prospective cohort of 5115 black and white
men and women examining the determinants of clinical and sub-clinical CVD. Participants
aged 18-30 at baseline (year 0) were recruited from four regions in the United States:
Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota and Oakland,
California. Enrollment at each site was balanced by sex, age (18-24 vs. 25-30), race, and
education. Follow up was performed at years 2, 5, 7, 10, 15, 20, 25, and 30 with retention
rates of 90%, 86%, 81%, 77%, 74%, 72%, 72%, and 71%, respectively. Our analysis
employed data from years 7 to 30 of the study. Additional details on design and recruitment
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for the study have been previously published.32 Approval from institutional review boards
was obtained annually by each site, and participants provided informed consent at each
exam.
Measurements
Standardized protocols were used at each center across all examinations.
Participants were asked to fast for at least 12 h before each examination and avoid smoking
or heavy physical activity at least 2 h prior.
CVD risk factors. Height and weight were measured at each examination while
wearing no shoes and light examination clothing. Height was measured via vertical ruler
to the nearest 0.5 cm and weight to the nearest 0.2 kg with a calibrated balance beam scale.
Body mass index (BMI) was calculated as weight in kg divided by height in meters squared.
Waist circumference was measured as the average of two measures taken at a level midway
between the lowest rib and iliac crest.
Smoking status was acquired via self-report.
Fasting blood draws were taken according to standard protocol.32 Glucose was
measured via hexokinase coupled to glucose-6-phosphate dehydrogenase.
Lipids and Lipoproteins. Total cholesterol and Triglycerides were determined from
plasma via enzymatic means.51 HDL-C was determined enzymatically after dextran sulfate
magnesium precipitations.52 LDL-C was estimated via Friedewald equation.53
Blood Pressure. Blood pressure was measured by trained technicians after
participants had rested for 5 minutes using a random zero sphygmomanometer (years 7
through 20). Year 25 and 30 blood pressure was measured using an Omron digital blood
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pressure monitor. All pressures were measured in triplicate with the average of the final
two measurements used for analysis.
Type 2 Diabetes Classification. Diabetes was classified as a fasting glucose >7.0
mmol/l (126 mg/dl) or the use of oral hypoglycemic medications or insulin. Diabetic status
was assessed in every exam from year 7 to 30.
Metabolic Syndrome Classification. Metabolic syndrome status at each exam was
defined as ≥3 of the following: (1) waist circumference >88 cm (35 in) for women and
>102 cm (40 in) for men, (2) HDL-C <40 mg/dl (1.0 mmol/L) for men or <50 mg/dl (1.3
mmol/L) for women, (3) fasting triglycerides ≥ 150 mg/dl (1.7 mmol/L), (4) blood pressure
(BP) ≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic or on treatment, or (5) fasting glucose
of 5.6 to 7.0 mmol/L (100 to 125 mg/dl). Participants reporting use of medications for
diabetes or hypertension were also classified as having met the criterion for elevated
glucose or blood pressure, respectively. Metabolic syndrome status was assessed in every
exam from year 7 to 30.
High Sensitivity C-Reactive Protein (hs-CRP). Fasting plasma samples from
year 7 exam were used to measure hs-CRP via a Roche latex-particle enhanced
immunoturbidimetric assay kit. Assays were read via Roche Modular P Chemistry
analyzer. Assay range for hs-CRP was 0.175 to 1100 μg/ml.33
Physical Activity (PA). Physical activity was measured via the CARDIA Physical
Activity History questionnaire, which inquires about time spent per week among 13
categories of PA over the past 12 months.54 A PA exercise units (EU) score was derived
from the questionnaire, with 300 EU corresponding to the recommended 150 minutes of
moderate physical activity per week.55
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Cardiorespiratory Fitness (CRF). Cardiorespiratory fitness was measured via
maximal graded treadmill testing using a modified Balke protocol at years 0, 7, and 20.34,
35

CRF was defined as time in minutes that participants were able to walk or run on the

treadmill.
Parity and Gestational Diabetes Mellitus (GDM). At each examination women
were asked if they had diabetes and if they had diabetes only during pregnancy (GDM).
Parity was also assessed at each examination and was defined as a live birth of >20 weeks’
gestation.
Nuclear Magnetic Resonance (NMR) Lipoprotein Profiles. Lipoprotein profile
analysis was performed on year 7 plasma samples via NMR spectroscopy at Liposcience,
Inc. (now LabCorp, Morrisville, NC) using the LipoProfile-3 algorithm.36 Each
measurement provides information on lipoprotein particle concentrations such as large,
medium, and small very low density lipoprotein (VLDL-P) and HDL-P, large and small
LDL-P, and intermediate density lipoprotein (IDL-P). Total VLDL-P, LDL-P, and HDL-P
concentrations were calculated by adding together their respective subclass concentrations
with IDL-P factoring into the overall LDL-P concentration. The weighted average particle
diameter for each lipoprotein is calculated as the sum of the lipoprotein subclass diameters
multiplied by its relative mass percentage as estimated from the amplitude of its methyl
NMR signal.
Lipoprotein Discordance Classification. Year 7 data was used to classify LDL
and HDL based lipoprotein discordance via three methods: 1) Median based discordance,
2) Continuous discordance, and 3) Quartiles of continuous discordance.
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For median based discordance, separate categorical discordance groups were made
for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater than
or equal to the race- and sex-specific median value as high and below the median as low.
Four exclusive cholesterol/particle discordant groups were made for both LDL and HDL
from these base categories: 1) Low/Low (concordantly Low: below the median for both
cholesterol content and particle concentration), 2) Low/High (discordant: below the
median for cholesterol content, at or above the median for particle concentration), 3)
High/Low (discordant: at or above the median for cholesterol content, below the median
for particle concentration), and 4) High/High (concordantly High: at or above the median
for both cholesterol content and particle concentration).
Lipoprotein cholesterol and particle concentrations were rank ordered into sex
specific percentiles to establish continuous discordance status. Continuous discordance
was then defined by subtracting an individual’s lipoprotein particle percentile from their
lipoprotein cholesterol percentile (positive percentile indicating higher cholesterol,
negative indicating higher particle concentration). Sex specific quartiles of continuous
discordance were also created and tested, with quartile one representing higher particle
concentrations and quartile four having higher cholesterol.
Statistical Analysis
The cross-sectional associations between median based HDL and LDL discordance status
and CVD risk factors at year 7 were assessed via multivariable linear regression in sexspecific models adjusted for age, race, BMI (except in anthropometric models. Partial
correlations between continuous lipoprotein discordance and CVD risk factors were
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assessed in the entire sample (e.g. not sex specific) and adjusted for age, sex, race, and bmi
(except in anthropometric models).
The longitudinal associations between year 7 LDL and HDL discordance status with
incident T2D and MetS over 23 years of follow up were assessed via Cox proportional
hazard regression. Three separate discordance models were examined with LDL or HDL
discordance as independent variables: 1) median based discordance, 2) continuous
discordance, and 3) quartiles of continuous discordance. All sex specific models were
adjusted for race, and the time varying covariates of age, smoking, and BMI. Femalespecific models were further adjusted for time varying parity and gestational diabetes. Age
and race interactions with discordance variables were also examined.
Results
Cross Sectional Analysis
Median cutoffs for HDL-C and HDL-P were 45.00 mg/dl and 22.43 µmol/L
respectively in men and 54.00 mg/dl and 21.86 µmol/L in women. Approximately 37%
and 35% of men and women, respectively were concordantly low for HDL (Low HDLC/Low HDL-P) while 36% of men and 34% of women were concordantly high. Thus,
about 27% of men and 31% of women had discordant levels of HDL-C and HDL-P (Tables
4.1 and 4.2).
In both sexes, when comparing all four HDL discordance groups at baseline, more
favorable risk factor profiles were primarily found in the two groups that had high HDL-C
(High HDL-C/Low HDL-P and High HDL-C/High HDL-P), regardless of discordance
status. Both High HDL-C groups had the lowest concentrations of triglycerides and LDLC, while also having higher concentrations of both large HDL-P and large LDL-P which
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contributed to higher mean HDL-P and LDL-P sizes (Tables 4.1 and 4.2). Furthermore,
these groups displayed lower BMI and waist circumferences than their low HDL-C
counterparts (Tables 4.3 and 4.4). In both male and female HDL discordance groups, the
High HDL-C/Low HDL-P discordant group displayed significantly lower LDL-C, small
LDL-P, and glycA concentrations compared to all other groups (Tables 4.1 to 4.4).
Median cutoffs for baseline LDL-C and LDL-P were 109.0 mg/dl and 1370.50
nmol/L respectively in men and 101.00 mg/dl and 1314.00 nmol/L respectively in women.
Approximately 43% of both men and women were concordantly low for LDL (Low LDLC/Low LDL-P) while about 42% were concordantly high. Thus, around 15% of both men
and women had discordant levels of LDL-C and LDL-P (Tables 4.5 and 4.6)
In both sexes, across all LDL discordance groups, more favorable risk factor
profiles were found in the two groups with the lowest LDL-P concentrations (Low LDLC/Low LDL-P and High LDL-C/Low LDL-P), regardless of LDL-C status. Both low LDLP groups had the lowest concentrations of triglycerides, small LDL-P, and glycA while
also having the highest mean HDL-P size (Tables 4.5 to 4.8). Males with LDL discordance
consisting of low LDL-P additionally displayed higher concentrations of HDL-C and large
HDL-P along with lower BMI and waist circumference measures (Tables 4.5 and 4.6). In
males, the concordantly Low group displayed significantly lower total cholesterol, LDLC, small HDL-P, and LDL-P concentrations than any other group, while the concordantly
High group displayed significantly higher levels of the same traits (Table 4.5). In females,
the concordantly Low group displayed the lowest BMI and waist circumference measures,
as well as total cholesterol and LDL-C concentrations. The female concordantly High
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group displayed the highest total cholesterol, LDL-C, small HDL-P, and LDL-P
concentrations of any other group (Tables 4.6 and 4.8).
Correlations between continuous lipoprotein discordance and CVD risk factors
revealed that continuous discordance levels were largely indicative of respective
lipoprotein subclass measures (Tables 4.9 and 4.10). HDL discordance was significantly
correlated to all risk factors except CRP, having strongest correlations with small HDL-P
concentration and mean HDL-P size (R=-0.73 and 0.66 respectively; P < 0.001. Table 4.9).
LDL discordance was significantly correlated to all risk factors except HDL-P, large HDLP concentration, and diastolic blood pressure, having strongest correlations with mean
LDL-P size and small LDL-P concentration (R=0.51 and -0.50 respectively; P,0.0001.
Table 4.10).
Longitudinal Analysis: Risk of Type 2 Diabetes and Metabolic Syndrome
No main effects of baseline HDL discordance status were found for males in
relation to T2D risk (Figure 4.1a), however, in females, both median based and continuous
baseline HDL discordance were significant risk factors for T2D (Figure 4.1b). In median
based analysis, the Low/High discordant group displayed significantly higher risk of T2D
than all groups (HR: 1.72; 95% CI 1.15 to 2.59 relative to Low/Low group). No other
significant observations were made for median based HDL discordance in females.
Regarding continuous discordance, every percentile difference higher for HDL-C
compared to HDL-P (i.e. higher HDL-C than HDL-P) was associated with a one percent
lower risk of T2D (HR: 0.990; 95% CI: 0.984 to 0.997; Figure 4.1b).
No main effects of baseline LDL discordance status were found for males in
relation to T2D risk (Figure 4.2a), however, an interaction with race were found for
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median based LDL discordance in females (Figure 4.2b). In median based analyses in
black females, the concordantly High LDL group experienced significantly higher risk of
incident T2D than all other groups (HR: 1.57; 95% CI: 1.03 to 2.40 relative to Low/Low
group). Continuous LDL discordance was not a significant predictor of incident T2D in
females (Figure 4.2b).
No main effects of HDL discordance group were found for males when it came to
MetS risk (Figure 4.3a). In females, median based HDL discordance was a significant
predictor of incident MetS, with the High/Low discordant group displaying significantly
lower risk of MetS than any other group (HR: 0.59; 95% CI: 0.40 to 0.88 relative to
Low/Low group). A significant interaction was found between race and continuous HDL
discordance in women. In white women only, each percentile difference higher between
HDL-C and HDL-P (i.e. higher HDL-C than HDL-P) was associated with a 1.8 percent
lower risk of MetS. (HR: 0.982; 95%CI 0.972 to 0.992; Figure 4.3b).
In males, LDL Discordance, regardless of the specific metric used, was not a
significant predictor of MetS risk (Figure 4.4a). In females, median based LDL
discordance was associated with incident MetS (Figure 4.4b). In median based LDL
discordance analysis, females in the Low/High LDL discordant group displayed
significantly higher risk of MetS than all other groups (HR: 1.83; 95% CI: 1.18 to 2.84
relative to Low/Low group; Figure 4.4b).
Discussion
Our study found cross sectional differences in multiple CVD risk factors among
median based lipoprotein discordance groups. In HDL discordance groups, CVD risk factor
profiles were more favorable for groups with high HDL-C while in LDL discordance
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groups risk factors favored lower LDL-P regardless of LDL-C status. The Low/High HDL
discordance group had the least favorable, while the High/Low HDL discordance group
displayed the most favorable risk factor profile in both men and women. People in the
Low/High HDL discordance group consistently (in both men and women) had the highest
level of triglycerides, LDL-C, small HDL-P and small LDL-P while the High/Low HDL
discordance group had the highest levels of these same traits. Similarly, the Low/High HDL
discordance group had the lowest mean HDL-P and LDL-P sizes while the High/Low
group had the highest mean sizes.
Cross sectional LDL discordance analysis in both men and women showed that the
high LDL-P groups had the least favorable risk factor profiles. No single high LDL-P group
was consistently worse than the other. However, each high LDL-P group was significantly
worse than both low LDL-P groups in several CVD risk factors.
Correlational analysis revealed that continuous discordance was largely indicative
of respective lipoprotein particle sizes (e.g. LDL discordance being most highly correlated
with LDL-P size). Interestingly, HDL discordance displayed consistently higher
correlations with most risk factors than that of LDL discordance. Furthermore, outside of
HDL specific measures, waist circumference and mean LDL-P size had the next largest
correlations with HDL discordance (both negative associations). Thus, continuous HDL
discordance was more strongly related to the majority of metrics relative to LDL
discordance, even outside of HDL specific traits.
While many studies have investigated the association between LDL discordance
and indices of CVD,

15, 17-23

none to date have examined the HDL or LDL discordance-

based risk of T2D or MetS. Furthermore, many previous studies used joint, and not sex
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specific discordance analyses. Nevertheless, we hypothesized that our findings would
parallel that of previous studies with higher risk favoring high LDL-P levels, regardless of
LDL-C status.
In male participants, lipoprotein discordance was not associated with either T2D
or MetS risk. In women lipoprotein discordance was significantly associated with both
T2D and MetS incidence. HDL discordance analysis suggests that both T2D and MetS risk
favors higher HDL-C and lower HDL-P in women. Higher continuous HDL discordance
(higher HDL-C/lower HDL-P) was negatively associated with T2D risk and the Low
Cholesterol/High Particle HDL discordance group (Median based) was at the highest risk
of T2D. In terms of MetS, the High cholesterol/Low Particle HDL discordance group was
at lowest risk. Our findings are contrary to CVD risk associations found my Tehrani et al.17
Using data from the Multi Ethnic Study of Atherosclerosis, authors found that higher levels
of HDL-P as opposed to HDL-C were associated with decreased risk of CVD events.17
LDL discordance analysis in women found that black women concordantly high
for LDL were at the highest risk of T2D. MetS risk was highest in the Low
Cholesterol/High Particle LDL median based group. Although these findings support risk
following that of LDL-P, they disagree in regard to LDL-C related discordance risk.
Strengths and Limitations
Our analysis is strengthened by the quality of the CARDIA dataset. The CARDIA
study has used standardized, quality-controlled data collection procedures over 30 years of
follow up with repeated exams. NMR lipoprotein subclass measurements were, however,
only measured at a single time point in year 7 of the study, thus we were not able to measure
changes in these measures over time, nor their association with T2D or MetS. Furthermore,
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we did not perform race specific discordance classifications, thus possible reasoning for
the race specific associations of discordance with either T2D or MetS are difficult to
ascertain.
Conclusions
Our study found multiple cross-sectional differences in CVD risk factor profiles of
lipoprotein discordance-based groups with continuous discordance levels being primarily
indicative of lipoprotein sizes and concentrations of their respective lipoprotein subclasses
(e.g. continuous HDL discordance being indicative of small HDL-P concentration).
Median based HDL discordance revealed more favorable risk factor profiles for high HDLC groups while median LDL discordance groups displayed better profiles in low LDL-P
groups. Furthermore, significant associations of lipoprotein discordance with T2D or MetS
risk were found only in women. which may be potentially influenced by GDM and/or
parity. While a body of work exists for LDL discordance, our study is the first to compare
risk factor profiles among HDL discordant groups. Thus, future research should continue
to examine the association between HDL discordance and incident CVD as well as
different CVD risk factors in further elucidating the role of HDL in CVD
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Table 4.1. Lipoprotein subclass outcomes for HDL discordant/concordant men in the CARDIA study at year seven exam
Low HDL-C/
Low HDL-P
N=650 (36.62%)

Low HDL-C/
High HDL-P
N=257 (14.48%)

High HDL-C/
Low HDL-P
N=237 (13.35%)

High HDL-C/
High HDL-P
N=631 (35.55%)

p
value
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Demographics
Age
32.09 (0.14)
32.51 (0.22)c
31.72 (0.23)b
31.85 (0.14)b
0.0429
% White
64.31
66.93
42.19
45.48
<.0001
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)
Continuous HDL Discordance
1.29 (0.64)*
-32.11 (1.00)*
36.84 (1.04)*
-1.42 (0.64)*
<.0001
Lipid Panel, (mg/dL)
Total Cholesterol
173.28 (1.41)b,d
184.58 (2.19)a,c
172.88 (2.28)b,d
185.52 (1.40)a,c
<.0001
c,d
c,d
a,b
Triglycerides
119.56 (3.58)
132.04 (5.58)
70.87 (5.81)
80.02 (3.56)a,b
<.0001
HDL-C
37.79 (0.36)*
41.83 (0.56)*
52.74 (0.58)*
58.50 (0.35)*
<.0001
LDL-C
112.45 (1.32)b,c
117.48 (2.07)*
105.55 (2.12)*
110.54 (1.30)b,c
0.001
Lipoprotein Particle Size (nm)
HDL-P size
8.68 (0.01)*
8.63 (0.02)*
9.15 (0.02)*
9.01 (0.01)*
<.0001
LDL-P size
20.58 (0.02)c,d
20.52 (0.03)c,d
21.03 (0.03)a,b
20.97 (0.02)a,b
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
20.03 (0.08)*
23.83 (0.12)*
20.95 (0.12)*
25.26 (0.08)*
<.0001
Small HDL-P
14.35 (0.10)*
17.94 (0.16)*
12.19 (0.17)*
15.90 (0.10)*
<.0001
c,d
c,d
Medium HDL-P
4.62 (0.08)
4.76 (0.12)
6.54 (0.13)*
7.12 (0.08)*
<.0001
Large HDL-P
1.06 (0.04)c,d
1.13 (0.06)c,d
2.23 (0.06)a,b
2.25 (0.04)a,b
<.0001
Total LDL-P
1481.60 (15.43)c,d 1501.01 (24.01)c,d 1306.05 (25.01)a,b 1361.29 (15.31)a,b
<.0001
Small LDL-P
973.82 (16.81)c,d 1012.45 (26.17)c,d 626.39 (27.26)*
697.22 (16.68)*
<.0001
Medium LDL-P
318.30 (13.54)
309.15 (21.07)
319.13 (21.95)
334.55 (13.44)
0.7362
Large LDL-P
189.47 (7.52)c,d
179.41 (11.71)c,d
360.53 (12.20)*
329.52 (7.46)*
<.0001
a
P<0.05 between low HDL-C/low HDL-P, b P<0.05 between low HDL-C/high HDL-P, c P<0.05 between high HDL-C/low
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses.
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.2. Lipoprotein subclass outcomes for HDL discordant/concordant women in the CARDIA study at year seven exam
Low HDL-C/
Low HDL-P
N=731 (34.56%)

Low HDL-C/
High HDL-C/
High HDL-P
Low HDL-P
N=343 (16.21%) N=327 (15.45%)

High HDL-C/
High HDL-P
N=715 (33.79%)

p
value
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Demographics
Age
32.06 (0.13)
32.11 (0.20)
31.87 (0.20)
32.10 (0.14)
0.781
% White
48.02
45.19
52.29
53.71
0.0303
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)
Continuous HDL Discordance
0.32 (0.63)*
-35.65 (0.9)*
39.9 (0.95)*
-2.19 (0.64)*
<.0001
Lipid Panel, (mg/dL)
Total Cholesterol
165.08 (1.15)*
179.81 (1.66)a,c
169.72 (1.74)*
182.54 (1.17)a,c
<.0001
Triglycerides
77.51 (1.86)*
92.16 (2.67)*
53.45 (2.81)*
66.74 (1.89)*
<.0001
HDL-C
44.38 (0.31)*
48.65 (0.44)*
63.08 (0.46)*
67.22 (0.31)*
<.0001
LDL-C
105.00 (1.06)*
112.43 (1.53)*
95.54 (1.60)*
101.51 (1.08)*
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
8.99 (0.01)*
8.88 (0.01)*
9.59 (0.02)*
9.35 (0.01)*
<.0001
LDL-P size
20.93 (0.02)*
20.82 (0.02)*
21.14 (0.03)*
21.03 (0.02)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
19.56 (0.07)*
23.33 (0.09)*
20.31 (0.10)*
24.53 (0.07)*
<.0001
Small HDL-P
12.05 (0.09)*
15.30 (0.13)*
10.21 (0.14)*
13.19 (0.10)*
<.0001
a,d
a,d
Medium HDL-P
5.81 (0.08)*
6.33 (0.12)
6.31 (0.13)
8.02 (0.09)*
<.0001
Large HDL-P
1.70 (0.04)c,d
1.70 (0.06)c,d
3.79 (0.06)*
3.32 (0.04)*
<.0001
b,c
b,c
Total LDL-P
1358.55 (12.84)
1476.95 (18.45)* 1220.06 (19.41)* 1336.98 (13.06)
<.0001
Small LDL-P
731.70 (13.97)b,c 881.69 (20.07)* 585.85 (21.12)*
713.57 (14.20)b,c
<.0001
Medium LDL-P
327.93 (10.62)c,d 319.43 (15.26)c,d 216.46 (16.05)a,b 221.25 (10.80)a,b
<.0001
Large LDL-P
298.92 (7.81)c,d
275.83 (11.22)c,d 417.75 (11.80)a,b
402.16 (7.94)a,b
<.0001
a
b
c
P<0.05 between low HDL-C/low HDL-P, P<0.05 between low HDL-C/high HDL-P, P<0.05 between high HDL-C/low
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses.
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.3. Cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the CARDIA study at year seven exam
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Low HDL-C/
Low HDL-C/
High HDL-C/
High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
High HDL-P
p
N=650 (36.62%) N=257 (14.48%) N=237 (13.35%) N=631 (35.55%)
value
Anthropometrics (not adjusted for BMI)
BMI (kg/m2)
27.93 (0.18)c,d
27.92 (0.28)c,d
24.76 (0.30)a,b
25.20 (0.18)a,b
<.0001
c,d
c,d
a,b
a,b
Waist Circumference (cm)
91.82 (0.44)
91.95 (0.70)
83.28 (0.72)
84.62 (0.44)
<.0001
Cardiorespiratory Fitness (min)
VO2max
11.24 (0.19)d
11.15 (0.30)
11.81 (0.35)
11.87 (0.20)a
0.0807
Blood Pressure (mmHg)
Systolic blood pressure
111.41 (0.44)b,d
114.22 (0.69)a,c
111.99 (0.72)b,d
114.04 (0.44)a,c
<.0001
b,d
a,c
b,d
a,c
Diastolic blood pressure
70.97 (0.39)
73.06 (0.60)
70.47 (0.63)
72.18 (0.38)
0.0023
Carbohydrate Metabolism
Glucose (mg/dL)
96.27 (0.78)c,d
97.91 (1.22)c,d
92.28 (1.27)a,b
93.07 (0.78)a,b
0.0006
c,d
a
a
Insulin (uU/mL)
15.71 (0.58)
14.80 (0.90)
13.14 (0.95)
13.36 (0.58)
0.0244
Inflammatory Markers
GlycA (µmol/L)
391.96 (2.43)c,d
385.42 (3.78)c,d
359.30 (3.93)*
375.94 (2.41)*
<.0001
b,d
a
a
C-Reactive Protein (ug/mL)
2.54 (0.17)
1.54 (0.27)
2.25 (0.28)
1.91 (0.17)
0.0059
a
b
c
P<0.05 between low HDL-C/low HDL-P, P<0.05 between low HDL-C/high HDL-P, P<0.05 between high HDL-C/low
HDL-P, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.4. Cardiovascular disease risk factor outcomes for HDL discordant/concordant women in the CARDIA study at year seven
exam
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Low HDL-C/
Low HDL-C/
High HDL-C/
High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
High HDL-P
p
N=731 (34.55%) N=343 (16.21%) N=327 (15.45%) N=715 (33.79%)
value
Anthropometrics (not adjusted for BMI)
BMI (kg/m2)
28.99 (0.24)c,d
28.80 (0.34)c,d
24.43 (0.36)a,b
25.03 (0.24)a,b
<.0001
c,d
c,d
Waist Circumference (cm)
84.64 (0.50)
85.66 (0.72)
73.74 (0.76)*
76.27 (0.51)*
<.0001
Cardiorespiratory Fitness
(min)
VO2max
8.35 (0.18)
8.21 (0.25)
8.72 (0.29)
8.89 (0.19)
0.0922
Blood Pressure (mmHg)
Systolic blood pressure
105.17 (0.42)d
105.70 (0.61)
103.96 (0.64)d
106.63 (0.43)a
0.0032
d
c
Diastolic blood pressure
67.40 (0.35)
67.75 (0.51)
66.65 (0.53)
68.36 (0.36)
0.0426
Carbohydrate Metabolism
Glucose (mg/dL)
90.38 (0.63)
91.09 (0.90)
88.34 (0.95)
89.17 (0.64)
0.119
b
b
b
Insulin (uU/mL)
13.75 (0.66)
17.01 (0.95)*
13.23 (1.01)
13.97 (0.67)
0.0171
Inflammatory Markers
GlycA (µmol/L)
408.75 (2.25)b,c
423.68 (3.24)*
379.11 (3.41)*
407.78 (2.29)b,c
<.0001
C-Reactive Protein (ug/mL)
3.40 (0.34)
3.73 (0.49)
4.33 (0.52)
3.36 (0.35)
0.4027
a
b
c
P<0.05 between low HDL-C/low HDL-P, P<0.05 between low HDL-C/high HDL-P, P<0.05 between high HDL-C/low HDLP, d P<0.05 between high HDL-C/high HDL-P, * P<0.05 between all other groups.
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.5. Lipoprotein subclass outcomes for LDL discordant/concordant men in the CARDIA study at year seven exam
Low LDL-C/
Low LDL-P
N=752 (42.87%)

Low LDL-C/
High LDL-P
N=134 (7.64%)

High LDL-C/
Low LDL-P
N=125 (7.13%)

High LDL-C/
High LDL-P
N=743 (42.36%)

p
value
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Demographics
Age
31.46 (0.13)b,d
32.41 (0.31)b
31.87 (0.32)
32.52 (0.13)a
<.0001
% White
50.66
56.72
60.8
57.74
0.0204
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)
Continuous LDL Discordance
0.07 (0.42)b,c
-24.59 (0.97)*
21.77 (1.01)*
0.57 (0.42)b,c
<.0001
Lipid Panel, (mg/dL)
Total Cholesterol
150.93 (0.87)*
169.70 (2.02)*
185.22 (2.10)*
208.15 (0.88)*
<.0001
Triglycerides
80.40 (2.01)b,d
130.38 (4.70)*
75.58 (4.87)b,d
103.37 (2.03)*
<.0001
b,d
a,c
b,d
a,c
HDL-C
50.40 (0.45)
46.78 (1.05)
50.54 (1.09)
45.69 (0.46)
<.0001
LDL-C
83.97 (0.71)*
96.27 (1.66)*
119.00 (1.73)*
141.26 (0.72)*
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
8.97 (0.01)b,d
8.82 (0.03)*
8.94 (0.03)b,d
8.74 (0.01)*
<.0001
LDL-P size
20.75 (0.02)*
20.39 (0.04)*
21.15 (0.04)*
20.84 (0.02)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
22.50 (0.11)
22.32 (0.26)
23.04 (0.27)
22.72 (0.11)
0.1242
Small HDL-P
14.29 (0.11)*
14.96 (0.26)a,d
15.23 (0.27)a,d
16.00 (0.11)*
<.0001
Medium HDL-P
6.27 (0.08)b,d
5.72 (0.19)a
6.10 (0.20)d
5.35 (0.08)a,c
<.0001
a,d
a,d
Large HDL-P
1.94 (0.04)*
1.63 (0.09)
1.71 (0.10)
1.38 (0.04)*
<.0001
Total LDL-P
1088.81 (8.79)* 1483.59 (20.50)* 1265.45 (21.26)* 1766.90 (8.87)*
<.0001
Small LDL-P
669.31 (14.99)* 1093.50 (34.95)* 564.59 (36.26)* 979.32 (15.12)*
<.0001
Medium LDL-P
205.69 (11.51)c,d 216.94 (26.83)c,d 318.87 (27.84)* 472.45 (11.61)*
<.0001
Large LDL-P
213.81 (7.00)*
173.15 (16.33)* 381.99 (16.94)*
315.13 (7.07)*
<.0001
a
b
c
P<0.05 between low LDL-C/low LDL-P, P<0.05 between low LDL-C/high LDL-P, P<0.05 between high LDL-C/low LDLP, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses.
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.6. Lipoprotein subclass outcomes for LDL discordant/concordant women in the CARDIA study at year seven exam
Low LDL-C/
Low LDL-P
N=897 (42.53%)

Low LDL-C/
High LDL-P
N=172 (8.16%)

High LDL-C/
Low LDL-P
N=158 (7.49%)

High LDL-C/
High LDL-P
N=882 (41.82%)

p
value
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Demographics
Age
31.87 (0.12)
31.94 (0.28)
32.35 (0.29)
32.19 (0.12)
0.185
% White
54.52
44.77
58.86
45.12
<.0001
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)
Continuous LDL Discordance
0.38 (0.45)b,c
-26.94 (1.06)*
24.91 (1.06)*
0.70 (0.46)b,c
<.0001
Lipid Panel, (mg/dL)
Total Cholesterol
149.15 (0.71)*
164.88 (1.66)*
180.39 (1.67)*
200.27 (0.73)*
<.0001
Triglycerides
59.64 (1.31)b,d
84.16 (3.06)a,c
63.29 (3.07)b,d
81.92 (1.34)a,c
<.0001
HDL-C
57.27 (0.43)d
56.50 (1.00)d
55.53 (1.00)
53.78 (0.44)a,b
<.0001
LDL-C
79.44 (0.57)*
91.04 (1.32)*
111.67 (1.33)*
129.60 (0.58)*
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
9.28 (0.01)b,d
9.15 (0.03)*
9.25 (0.03)b,d
9.08 (0.01)*
<.0001
LDL-P size
20.88 (0.01)*
20.69 (0.03)*
21.31 (0.03)*
21.08 (0.01)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
21.69 (0.09)b,d
22.24 (0.22)a
21.67 (0.22)d
22.25 (0.10)a.c
0.0002
c,d
d
a,d
Small HDL-P
12.06 (0.10)
12.40 (0.22)
12.85 (0.23)
13.37 (0.10)*
<.0001
Medium HDL-P
6.79 (0.08)b,c
7.19 (0.19)*
6.28 (0.19)a,b
6.63 (0.08)b
0.0042
c,d
d
a,d
Large HDL-P
2.85 (0.05)
2.65 (0.11)
2.53 (0.11)
2.25 (0.05)*
<.0001
Total LDL-P
1058.04 (7.07)* 1455.07 (16.46)* 1207.26 (16.53)*
1660.40 (7.20)*
<.0001
Small LDL-P
612.92 (11.81)* 994.78 (27.49)*
478.78 (27.61)*
840.9 (12.03)*
<.0001
Medium LDL-P
182.27 (9.13)
195.83 (21.25)
276.12 (21.34)
385.31 (9.30)
<.0001
Large LDL-P
262.85 (6.63)c,d 264.45 (15.42)c,d 452.35 (15.48)a,b
434.19 (6.75)a,b
<.0001
a
b
c
P<0.05 between low LDL-C/low LDL-P, P<0.05 between low LDL-C/high LDL-P, P<0.05 between high LDL-C/low
LDL-P, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups
Values are presented as mean (standard error).Continuous discordance and age were assessed via univariable regression analyses.
Race percentage was assessed via chi-square. Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.7. Cardiovascular disease risk factor outcomes for LDL discordant/concordant men in the CARDIA study at year seven exam
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Low LDL-C/
Low LDL-C/
High LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
p
N=752 (42.87%) N=134 (7.64%) N=125 (7.13%) N=743 (42.36%)
value
Anthropometrics (not adjusted for BMI)
BMI (kg/m2)
25.23 (0.17)b,d
28.17 (0.39)a,c
25.12 (0.41)b,d
27.64 (0.17)a,c
<.0001
b,d
a,c
b,d
Waist Circumference (cm)
84.69 (0.41)
92.54 (0.96)
84.14 (0.99)
91.05 (0.41)a,c
<.0001
Cardiorespiratory Fitness (min)
VO2max
11.72 (0.18)
11.46 (0.43)
11.55 (0.49)
11.39 (0.18)
0.6578
Blood Pressure (mmHg)
Systolic blood pressure
112.00 (0.41)d
113.76 (0.95)
111.64 (0.99)
113.60 (0.41)a
0.0236
d
a
Diastolic blood pressure
70.59 (0.35)
71.23 (0.82)
71.05 (0.85)
72.69 (0.35)
0.0005
Carbohydrate Metabolism
Glucose (mg/dL)
93.00 (0.66)b,d
97.36 (1.54)a,c
92.36 (1.59)b,d
95.37 (0.67)a,c
0.0104
Insulin (uU/mL)
14.55 (0.54)
15.95 (1.27)
13.26 (1.28)
13.91 (0.54)
0.3673
Inflammatory Markers
GlycA (µmol/L)
375.94 (2.21)*
396.54 (5.16)*
360.01 (5.35)*
384.18 (2.23)*
<.0001
C-Reactive Protein (ug/mL)
2.30 (0.16)
2.45 (0.37)
1.77 (0.39)
1.94 (0.16)
0.2462
a
P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-P,
d
P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.8. Cardiovascular disease risk factor outcomes for LDL discordant/concordant women in the CARDIA study at year seven
exam
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Low LDL-C/
Low LDL-C/
High LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
p
N=897 (42.53%) N=172 (8.16%) N=158 (7.49%)
N=882 (41.82%)
value
Anthropometrics (not adjusted for BMI)
BMI (kg/m2)
25.43 (0.22)*
26.94 (0.52)a,d
27.50 (0.52)a
28.34 (0.22)a,d
<.0001
a,d
a,d
Waist Circumference (cm)
76.87 (0.46)*
80.92 (1.10)
80.88 (1.10)
83.65 (0.47)*
<.0001
Cardiorespiratory Fitness (min)
VO2max
8.84 (0.17)
8.24 (0.38)
8.69 (0.36)
8.31 (0.16)
0.1174
Blood Pressure (mmHg)
Systolic blood pressure
105.13 (0.38)
106.09 (0.88)
104.82 (0.88)
105.98 (0.38)
0.3258
d
a
Diastolic blood pressure
66.80 (0.32)
67.57 (0.73)
67.07 (0.74)
68.62 (0.32)
0.0009
Carbohydrate Metabolism
Glucose (mmol/L)
88.50 (0.55)d
90.87 (1.27)
88.81 (1.27)
90.78 (0.56)a
0.0212
Insulin (pmol/L)
13.72 (0.59)
16.09 (1.41)
12.97 (1.39)
14.63 (0.60)
0.2969
Inflammatory Markers
GlycA (µmol/L)
395.7 (2.03)b,d
422.53 (4.73)a,c 393.01 (4.75)b,d
416.46 (2.07)a,c
<.0001
C-Reactive Protein (mg/dL)
3.71 (0.31)
3.97 (0.71)
2.08 (0.72)
3.64 (0.31)
0.18
a
b
c
P<0.05 between low LDL-C/low LDL-P, P<0.05 between low LDL-C/high LDL-P, P<0.05 between high LDL-C/low LDL-P,
d
P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all other models were adjusted for age, race, and year seven
BMI.

Table 4.9. Correlations of CVD Risk Factors with Baseline Continuous HDL
Discordance
Continuous HDL
Discordance
Correlation

p
Value

Lipid panel, (mg/dL)
Total Cholesterol
-0.15
<.0001
Triglycerides
-0.28
<.0001
HDL-C
0.35
<.0001
LDL-C
-0.19
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
0.66
<.0001
LDL-P size
0.31
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
-0.47
<.0001
Small HDL-P
-0.73
<.0001
Medium HDL-P
0.09
<.0001
Large HDL-P
0.47
<.0001
Total LDL-P
-0.23
<.0001
Small LDL-P
-0.29
<.0001
Medium LDL-P
-0.06
0.0003
Large LDL-P
0.25
<.0001
Anthropometrics (not adjusted for year 7 BMI)
BMI (kg/m2)
Waist Circumference (cm)
Cardiorespiratory Fitness (min)

-0.27
-0.33

VO2max
0.08
Blood Pressure (mmHg)
Systolic Blood Pressure
-0.09
Diastolic Blood Pressure
-0.11
Carbohydrate Metabolism
Glucose (mg/dL)
-0.12
Insulin (uU/mL)
-0.06
Inflammatory Markers
GlycA (µmol/L)
-0.23
C-Reactive Protein (ug/mL)
0.02
All models adjusted for year 7 age, race, sex, and BMI (except
anthropometrics).
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<.0001
<.0001
0.0063
<.0001
<.0001
<.0001
0.0001
<.0001
0.2714

Table 4.10. Correlations of CVD Risk Factors with Baseline Continuous
LDL Discordance
Continuous LDL
Discordance
Correlation

p
Value

Lipid panel, (mg/dL)
Total Cholesterol
0.18
<.0001
Triglycerides
-0.28
<.0001
HDL-C
0.04
0.022
LDL-C
0.27
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
0.13
<.0001
LDL-P size
0.51
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
0.00
0.8342
Small HDL-P
0.03
0.045
Medium HDL-P
-0.05
0.0023
Large HDL-P
0.02
0.1586
Total LDL-P
-0.24
<.0001
Small LDL-P
-0.50
<.0001
Medium LDL-P
0.13
<.0001
Large LDL-P
0.36
<.0001
Anthropometrics (not adjusted for year 7 BMI)
BMI (kg/m2)
Waist Circumference (cm)
Cardiorespiratory Fitness (min)

-0.06
-0.09

VO2max
0.05
Blood Pressure (mmHg)
Systolic Blood Pressure
-0.07
Diastolic Blood Pressure
-0.02
Carbohydrate Metabolism
Glucose (mg/dL)
-0.07
Insulin (uU/mL)
-0.09
Inflammatory Markers
GlycA (µmol/L)
-0.18
C-Reactive Protein (ug/mL)
-0.04
All models adjusted for year 7 age, race, sex, and BMI (except
anthropometrics).
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0.0007
<.0001
0.0637
<.0001
0.2468
<.0001
<.0001
<.0001
0.0131

a

b

Figure 4.1. HDL Discordance Based Risk of Type 2 Diabetes in Males (a) and Females
(b) Male models were adjusted for race and time varying age, BMI, and smoking. Female
models additionally adjusted for time varying gestational diabetes, and parity

a

b

Figure 4.2. LDL Discordance Based Risk of Type 2 Diabetes in Males (a) and Females
(b). Male models were adjusted for race and time varying age, BMI, and smoking.
Female models additionally adjusted for time varying gestational diabetes, and parity
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Male Risk of Metabolic Syndrome
HDL Disocordance Metric
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MEDIAN BASED DISCORDANCE (P=0.0598)
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Low HDL-C/Low HDL-P (reference)
Low HDL-C/High HDL-P
High HDL-C/Low HDL-P
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Figure 4.3. HDL Discordance Based Risk of Metabolic Syndrome in Males (a) and
Females (b). Male models were adjusted for race and time varying age, BMI, and
smoking. Female models additionally adjusted for time varying gestational diabetes, and
parity.

a

b

Figure 4.4. LDL Discordance Based Risk of Metabolic Syndrome in Males (a) and
Females (b). Male models were adjusted for race and time varying age, BMI, and
smoking. Female models additionally adjusted for time varying gestational diabetes, and
parity.
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CHAPTER 5
DISCORDANCE BETWEEN LIPOPROTEIN CHOLESTEROL AND PARTICLE
CONCENTRATIONS AND EXERCISE INDUCED CHANGES IN CARDIOVASCULAR
DISEASE RISK FACTORS
Abstract
Purpose: To examine the association between lipoprotein discordance status and exercise
induced changes in lipoprotein discordance, as well as multiple cardiovascular disease risk
factors among participants from two previously completed exercise interventions.
Methods: The HERITAGE Family Study (N=715) was a progressive 20-week
standardized endurance training intervention. The HART-D study (N=214) was a ninemonth exercise intervention in type 2 diabetics with a control group and three training
groups: 1) Aerobic training only (AT), 2) Resistance training only (RT), 3) Combined
AT/RT. Four exclusive HDL and LDL discordance groups were created based on baseline
median lipoprotein cholesterol/particle concentrations as follows: 1) low/low (< median
for both cholesterol and particle), 2) low/high (< median cholesterol, ≥ median particle), 3)
high/low, and 4) high/high. Continuous discordance levels were created at baseline and
post intervention by subtracting individual particle percentile ranking from cholesterol
percentile ranking (e.g. HDL-C – HDL-P). The association between sex-specific median
based (HERITAGE) and continuous (HART-D) lipoprotein discordance and exercise
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training induced changes in multiple CVD risk factors was assessed via multivariable linear
regression.
Results: In HERITAGE women, low HDL-P groups (Low/Low and High/Low)
experienced mean increases in continuous HDL discordance with exercise training, while
high HDL-P groups (Low/High and High/High) experienced decreases (p<0.05 for all).
Only discordant HDL groups in men experienced significant continuous HDL discordance
changes, with the Low/High group experiencing a mean decrease and the High/Low group
increasing (p<0.0001 for both). In both men and women, the two LDL discordant groups
were the only to change continuous LDL discordance, with the High/Low group
experiencing a mean decrease and the Low/High group increasing (p<0.01 for all). In
HART-D, baseline continuous HDL discordance was significantly associated (p<0.05)
with changes in continuous HDL discordance (β=-0.273), mean HDL-P size (β=0.003),
and concentrations of triglycerides (β=0.515), total HDL-P (β=0.016), large HDL-P
(β=0.007), and small HDL-P (β=-2.163) Baseline continuous LDL discordance was
significantly associated (p<0.05) with changes in continuous LDL discordance (β=-0.495),
LDL-C (β=-0.266), and body fat percentage (β=-0.014).
Conclusions: Lipoprotein discordance status is primarily associated with exercise training
induced changes in lipoprotein subclass measures. In general, exercise training decreased
LDL discordance but did not improve continuous HDL discordance. Our study shows that
lipoprotein discordance is minimally predictive of exercise training responses outside of
lipoprotein subclass measures.
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1. Introduction
Limitations in our ability to predict cardiovascular disease (CVD) risk have led to
increased clinical interest in identifying novel risk markers and refining the measurement
of traditional risk factors, such as the cholesterol content of low-density (LDL-C) and
high-density (HDL-C) lipoproteins.56 Both LDL and HDL are largely heterogeneous
lipoproteins, varying in size, density, composition and function and thus may not be solely
represented by their cholesterol content. Advanced techniques such as nuclear magnetic
resonance (NMR) are able to provide subclass measurements of these lipoproteins,
revealing their diversity and offering alternative measures in estimating CVD risk.
One popular alternative to cholesterol content is measuring the concentration of
both LDL and HDL particles (LDL-P and HDL-P respectively). Both total LDL-P and
HDL-P often outperform their respective cholesterol contents in CVD risk estimation.14-16
However, these analyses use cholesterol content and particle concentration separately in
their statistical models, thus treating them as independent predictors of CVD risk. As LDLC and HDL-C are not biologically independent of their particle concentrations, treating
them a as independent predictors fails to account for both the biological similarities and
differences represented by each variable.29
Lipoprotein discordance, a ratio between cholesterol content and particle
concentration (e.g. LDL-C/LDL-P), accounts for both the biological similarities and
differences represented by each variable. This ratio represents the relative similarity
between an individual’s cholesterol and particle concentration measures by ranking them
by their cholesterol levels and particle concentrations separately within their respective
study cohort. Studies examining the association of LDL discordance (LDL-C/LDL-P) on
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cardiovascular risk15, 17-23 have found that in concordant groups, both LDL-C and LDL-P
equally predict risk. However, in discordant LDL-C/LDL-P (e.g., high LDL-C/low LDLP), risk of adverse cardiovascular events is positively associated with LDL-P.18,
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Regarding HDL discordance, higher levels of HDL discordance (higher HDL-P and lower
HDL-C) have been associated with decreased CVD risk.17 This relationship, however, may
be confounded by disease status such as diabetes or metabolic syndrome.17
Exercise is well known to improve the lipoprotein profile and individual lipoprotein
subclasses, including increases in HDL-C and large HDL-P concentrations, along with
decreases in small LDL-P concentration and increases in LDL-P size.24, 25 However, no
studies have examined the effects of regular exercise on LDL and HDL discordance.
Furthermore, the association between baseline discordance status and exercise induced
changes in CVD risk factors has yet to be explored. Therefore, the purpose of this study is
to assess the effects of regular exercise on LDL and HDL discordance, as well as examine
the association of baseline discordance status on exercise induced changes in multiple CVD
risk factors.
2. Methods
Data from two completed studies, spanning four distinct training programs, were
used for the present analyses. Details of each individual study are given below.
2.1. HERITAGE Family Study
Full details of the design and methods of the HERITAGE Family Study (hereafter
HERITAGE) have been previously reported.37 Briefly, HERITAGE included 715 black
(34%), and white men and women (55%) aged 17-65 years. Participants were sedentary at
baseline with a BMI less than 40 kg/m2 and normotensive to mildly hypertensive (<160/100
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mmHg). Each participant completed a 20-week exercise intervention which consisted of
three exercise sessions per week on a cycle ergometer. Exercise sessions started at 30
minutes at the heart rate associated with 55% of maximal oxygen consumption (VO2max)
for the first two weeks and progressed to a target of 50 minutes at 75% of VO2max for each
session, which was maintained for the final six weeks of training.37
2.2. HART-D Study
The design, recruitment, and methods of HART-D have been previously described
.57 The HART-D study included 214 sedentary (54.7% White, 40.6% Black, 3.7% Asian,
0.5% Hispanic, 0.5% Other) men and women (63.6%) aged 30 – 75 years with type 2
diabetes and HbA1c levels of 6.5% to 11.0%. Participants had a BMI less than 48 kg/m2,
blood pressure below 160/100 mmHg, fasting triglycerides below 500 mg/dL, urine protein
less than 100 mg/dL and serum creatinine under 1.5 mg/dL. Further exclusion criteria
included use of an insulin pump, history of stroke, advanced neuropathy or retinopathy, or
any serious medical condition that prevented participants from adhering to the protocol or
exercising safely.
HART-D was a nine-month exercise intervention with a control group and three
exercise training groups: aerobic exercise training only (AT), resistance exercise training
only (RT), and a combination of aerobic and resistance training (AT/RT). The non-exercise
control group was asked to maintain their normal level of activity during the 9 months and
were offered weekly stretching and relaxation classes.
The AT group exercised three to five days/week at an intensity of 50–80% of their
VO2max for a total dose of 12 kcal/kg/week. Caloric expenditure was adjusted weekly based
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upon weight changes. American College of Sports Medicine equations were used to
calculate caloric expenditure and therefore time required per exercise session.
The RT group trained 3 days/week. Each session included two sets of four upper
body exercises (chest press, lateral pull-down, military press, and seated row), three sets of
three lower body exercises (leg press, leg ex- tension, and hamstring curl), and two core
exercises (abdominal crunches and back extensions). Each set consisted of 10-12
repetitions. The prescribed weight was increased when participants could complete 12
repetitions on the last set of each exercise for two consecutive sessions.
The AT/RT group was prescribed 3 days/week of aerobic exercise at a dose of 10
kcal/kg/week and 2 resistance training sessions per week. Resistance exercises and their
progression were the same as those in the resistance training only group, however, only
one set of each exercise was performed.
2.3. Blood Samples
Blood samples were collected from an antecubital vein into vacutainer tubes
containing EDTA. Samples were taken in the morning after a 10 (HART-D) or 12
(HERITAGE) hour fast. Samples for HERIATAGE were taken twice at baseline and 24
and 72 hours after the last exercise training session. Samples for the HART-D study were
collected within 48 to 96 hours of the final exercise bout.
2.4. Lipids and Lipoproteins
In HERITAGE plasma very low-density lipoproteins (VLDL) were isolated via
ultracentrifugation. HDL fractions were obtained after precipitation of LDL in the
infranatant by the heparin-manganese chloride method. Total cholesterol and triglyceride

64

levels were determined in plasma and lipoproteins via enzymatic methods (Technicon RA500 Analyzer; Bayer Corporation Inc., Tarrytown, NY).
For HART-D, fasting blood lipids (total cholesterol, LDL-C, HDL-C, and
triglycerides) were analyzed on a DXC 600 Pro Clinical Chemistry Analyzer (Beckman
Coulter Inc, Brea, California).
2.5. Lipoprotein Subclass Profiles and GlycA
Comprehensive lipoprotein profiling and GlycA analysis were performed on
baseline and post-training plasma samples via NMR spectroscopy at Labcorp, Inc.
(Morrisville, NC) using either the LipoProfile-3 (HERITAGE) or LipoProfile-4 (HARTD) algorithm.36 Each measurement provides information on lipoprotein particle
concentrations, including total, large, medium, and small HDL-P and LDL-P
concentrations and mean HDL-P and LDL-P size. NMR signal amplitudes originating from
the N-acetyl methyl group protons of N-acetylglucosamine residues on the glycan branches
of glycoproteins were used to quantify GlycA concentrations.
2.6 Defining HDL/LDL Discordance/Concordance Groups
Baseline HDL and LDL based lipoprotein discordance for both studies were
classified via two methods: 1) Median based discordance and 2) Continuous discordance.
Post-intervention discordance was also classified via continuous discordance.
For median based discordance, separate categorical discordant/concordant groups were
made for LDL and HDL by denoting LDL-C, LDL-P, HDL-C, and HDL-P values greater
than or equal to the sex-specific median value as high and below the median as low. Four
exclusive cholesterol/particle concordant/discordant groups were made for both LDL and
HDL from these base categories: 1) Low/Low (Concordantly low: below the median for
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both cholesterol content and particle concentration), 2) Low/High (Discordant: below the
median for cholesterol content, at or above the median for particle concentration), 3)
High/Low (Discordant: at or above the median for cholesterol content, below the median
for particle concentration), and 4) High/High (Concordantly high: at or above the median
for both cholesterol content and particle concentration). Note that median based
discordance/concordance groups as a whole will be referred to as discordance groups from
here forward unless referencing a specific group.
Lipoprotein cholesterol and particle concentrations were rank ordered into sex
specific percentiles to establish continuous discordance status. Continuous discordance
was then defined by subtracting an individual’s lipoprotein particle percentile from their
lipoprotein cholesterol percentile.
2.7. CVD risk factor measurements.
Common CVD risk factor measurements for both HERITAGE and HART-D were
BMI, body fat percentage, VO2max, resting blood pressure, fasting glucose, fasting insulin
and CRP.37, 41, 47, 48, 57, 58 Risk factor measurements unique to HERITAGE were visceral
adipose tissue, insulin sensitivity index, lipoprotein lipase and hepatic lipase.37,
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HART-D analyses uniquely measured waist circumference and hemoglobin A1C.57,
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Methodology for CVD risk factor measurements can be found in supplemental methods.
2.8. Statistical Analysis
The association of baseline median based (HERITAGE) or continuous (HART-D)
LDL and HDL discordance status with exercise induced changes in CVD risk factors was
assessed via multivariable linear regression. HERITAGE models were stratified by sex and
adjusted for age, race, baseline BMI, and baseline trait (i.e. adjusting for baseline HDL-C
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when assessing for changes in HDL-C). HART-D models were adjusted for age, race, sex,
baseline BMI, cholesterol medication, and baseline trait. HART-D models were
additionally adjusted for training group assignment (Control group not included) with the
interaction between discordance and intervention group assignment also being explored.
3. Results
3.1. HERITAGE
HDL Discordance
Median cutoffs for baseline HDL-C and total HDL-P were 35.57 mg/dl and 28.60
µmol/L respectively in men and 42.72 mg/dl and 29.40 µmol/L respectively in women.
Approximately 34% and 33% of men and women respectively, were concordantly low for
HDL (Low HDL-C/Low HDL-P) while 35% of men and 34% of women were concordantly
high. Thus about 31% of men and 33% of women had discordant levels of HDL-C and
HDL-P (Table 5.1 and 5.2).
In both male and female HDL discordance groups at baseline, more favorable risk
factor profiles were primarily found in the two groups that had high HDL-C (High HDLC/Low HDL-P and High HDL-C/High HDL-P), regardless of discordance status. Both
High HDL-C groups had the largest mean LDL-P size and concentration of large HDL-P
(Tables 5.1 and 5.2).
In males, High HDL-C groups displayed the lowest BMI (25.39 and 26.38 kg/m2
respectively for High/Low and High/High vs 28.06 and 28.62 respectively for Low/Low
and Low/High groups) and visceral adipose tissue (84.78 and 85.87 cm2 respectively for
High/Low and High/High vs 106.05 and 113.86 for Low/Low and Low/High groups). The
concordantly high group had significantly higher insulin sensitivity than all groups. The
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Low/High HDL discordant group had the highest triglycerides and small LDL-P
concentrations of all groups (Tables 5.1 and 5.3).
In females, high HDL-C groups displayed the lowest BMI, percent body fat, and
visceral adiposity as well. The High/Low discordant group had significantly lower
triglycerides and small LDL-P concentration than all other groups. The Low/High
discordant group had the highest visceral abdominal fat, and triglycerides, small LDL-P,
and fasting glucose concentrations (Tables 5.2 and 5.4).
Regarding exercise induced changes in risk factors, male HDL discordance groups
displayed significant trends for changes in continuous HDL discordance, mean HDL-P size
and total HDL-P and large HDL-P concentrations. Low HDL-P groups (Low/Low and
High/Low) experienced mean increases in continuous HDL discordance while high HDLP groups (Low/High and High/High) experienced mean decreases with exercise training.
On average, both High HDL-C groups increased HDL-P size, as well as total and large
HDL-P concentrations, while the two Low HDL-C groups exhibited mean decreases in
each of these outcomes (Tables 5.5 and 5.7).
Similar to men, female HDL discordance groups displayed a trend for exercise
induced changes continuous HDL discordance with Low HDL-P groups experiencing
mean increases in continuous HDL discordance while high HDL-P groups experienced
mean decreases with exercise training. The Low/High HDL discordant group showed
significantly different changes in HDL-P size, LDL-P size, and small LDL-P concentration
relative to all other groups, with the direction of change opposite of that compared to all
three other groups for each of these traits. Specifically, this group was the only group to
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decrease HDL-P or LDL-P size and increase small LDL-P concentration with training
(Tables 5.6 and 5.8).
LDL Discordance
Median cutoffs for baseline LDL-C and total LDL-P were 113.08 mg/dl and
1048.50 nmol/L respectively in men and 109.21 mg/dl and 889.00 nmol/L respectively in
women. Approximately 41% of both men and women were concordantly low for LDL
(Low LDL-C/Low LDL-P) while 43% of men and 41% of women were concordantly high.
Thus, about 16% of men and 18% of women had discordant levels of LDL-C and LDL-P
(Table 5.9 and 5.10).
In both male and female LDL discordance groups, more favorable risk factor
profiles were found in the two groups with the lowest LDL-P concentrations (Low LDLC/Low LDL-P and High LDL-C/Low LDL-P), regardless of LDL-C/discordance status
(Tables 5.9 to 5.12). Both low LDL-P groups had the lowest BMI and triglycerides and
small LDL-P concentrations. The concordantly low groups displayed the lowest total
cholesterol, LDL-C, and total LDL-P concentrations of all groups. The concordantly High
groups displayed the highest total cholesterol, LDL-C, and LDL-P concentrations of all
groups. Furthermore, the High/High concordant groups in both sexes had the smallest mean
HDL-P size (Tables 5.9 and 5.10), while in females the concordantly high group had the
lowest insulin sensitivity (Table 5.12). In males, Low LDL-P groups displayed the lowest
percent body fat (Tables 5.11).
Regarding exercise induced changes in risk factors, male LDL discordance groups
displayed significant trends for differential changes in continuous LDL discordance as well
as total and large LDL-P concentrations (Tables 5.13 and 5.14). In males, both low LDL-
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P groups (Low LDL-C/Low LDL-P and High LDL-C/Low LDL-P) experienced mean
decreases in continuous LDL discordance while high LDL-P groups experienced increases.
Both high LDL-C groups increased total LDL-P concentration, as opposed to decreased
concentrations in low LDL-C groups. The Low/Low concordant group was the only group
to display an overall mean decrease in Large LDL-P (Table 5.13). In female LDL
discordance groups, significant associations were found for continuous LDL discordance
triglycerides and small and large LDL-P concentrations (Table 5.14). The High/Low LDL
discordant group was the only to experience a mean decrease in continuous LDL
discordance. The High/High concordant group was the only group to have a mean increase
in triglycerides, while the Low/Low concordant group was the only to decrease small LDLP with training. All groups except the Low/High discordant group increased large LDL-P
concentration (Table 5.14).
3.2. HART-D Study
Median cutoffs for baseline HDL-C and total HDL-P were 47.60 mg/dl and 22.00
µmol/L respectively. Median cutoffs for baseline for LDL-C and total LDL-P were 93.50
mg/dl and 1060.50 nmol/L respectively (Tables 5.17 and 5.19).
Median based HDL discordance groups with High HDL-C displayed favorable risk
factor profiles with the highest mean HDL-P size, medium and large HDL-P
concentrations, and the lowest small LDL-P concentrations (Table 5.17). Median based
LDL discordance groups with Low LDL-P displayed favorable risk factor profiles with the
lowest small LDL-P concentrations (Table 5.19)
Significant associations of baseline continuous HDL discordance were found with
exercise induced changes in continuous HDL discordance, triglycerides, mean HDL-P size,
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and total and large HDL-P and small LDL-P concentrations (Table 5.21). No significant
interactions between HDL discordance and group were found. Significant associations of
continuous LDL discordance were found with exercise induced changes in continuous LDL
discordance, LDL-C concentration, and body fat (Table 5.22). A significant interaction
between continuous LDL discordance and group was found for systolic blood pressure
although none of the groups displayed a significant change in this outcome.
4. Discussion
Our study found multiple cross-sectional differences in CVD risk factor profiles
between lipoprotein discordance groups among relatively healthy (HERITAGE) and type
2 diabetic (HART-D) adults. In both studies, risk factor profiles tended to follow HDL-C
levels regardless of HDL discordance status, with the higher HDL-C groups displaying
more favorable profiles. The Low HDL-C/High HDL-P discordant group displayed the
worst baseline risk factor profile through all studies, displaying the highest concentrations
of triglycerides, small HDL-P and small LDL-P, all of which have been positively
associated with CVD risk.61, 62 Furthermore, HERITAGE females in the Low HDL-C/High
HDL-P group increased atherogenic small LDL-P concentrations with exercise training,
while all other groups experienced presumed beneficial decreases in small LDL-P. With
the limited literature on HDL discordance, our study sheds light on the association between
HDL discordance and multiple CVD risk factors in both healthy and diabetic adults.
In LDL discordance groups, risk factor profiles tended to track with LDL-P
concentration, with low LDL-P groups displaying more favorable profiles. These findings
are consistent with prior literature showing that risk factor profiles and risk of adverse CVD
related outcomes is lower in those with low LDL-P concentrations.15, 17-23
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Knowing the individual associations of lipoprotein measures, as well as the
association of lipoprotein discordance, with CVD outcomes and risk factors it is valuable
to examine whether exercise reduces/corrects lipoprotein discordance and whether
discordance results in differential changes to individual lipoprotein and risk factor
measures. In both studies, main effects of HDL discordance were primarily seen in HDL
metrics such as HDL-P size and large HDL-P concentration. Specifically, those with High
HDL-C tended to have more favorable changes in these metrics with training. In males
from HERITAGE, the Low HDL-C groups had the lowest large HDL-P concentrations at
baseline and showed a mean decrease in large HDL-P with training, while both High HDLC groups showed mean increases. Overall, in HERITAGE exercise training resulted in
decreased continuous HDL discordance in High HDL-P groups and increased discordance
in Low HDL-P groups. Increases in discordance would indicate a higher post-training
percentile for HDL-C, a lower post-training percentile for HDL-P or a combination of both.
Decreases in discordance would essentially mean opposite responses (relative to increases)
in post training lipoprotein percentiles. As continuous discordance is based on an
individual’s ranks of lipoprotein metrics (cholesterol or particle concentration) within the
study cohort, using continuous discordance changes may be misleading as all participants
may have seen some level of change that inherently affects the rankings of all individuals
within the study. Thus, changes in individual lipoprotein subfractions may be more
informative.
Similarly, in the HART-D study, a higher baseline continuous HDL discordance
(more HDL-C than HDL-P) was associated with increased large HDL-P concentration with
exercise training. Thus, those with higher concentrations of large HDL-P and/or larger
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mean HDL-P size tended to further increase these values with training, whereas those with
lower concentrations of large HDL-P or smaller mean HDL-P size tended to decrease these
values with training. Basleine HDL discordance was also negatively associated with
changes in continuous HDL discordance. Interestingly, continuous HDL discordance was
also negatively associated with training induced changes in triglycerides and small LDLP. Therefore, beneficial training induced changes were associated with higher baseline
HDL-C.
Similar to the findings for HDL, the association of LDL discordance with traininginduced changes in risk factors was primarily seen for changes in LDL metrics such as
LDL-C and large LDL-P. In both sexes in HERITAGE, those above the median for LDLC levels (High LDL-C) were the only individuals to significantly increase large LDL-P
concentrations with training, regardless of LDL discordance status. In HART-D, higher
continuous LDL discordance (higher LDL-C than LDL-P) was negatively associated with
changes continuous LDL discordance and LDL-C. Both results suggest potential
regression to the mean. LDL discordance was not significantly associated with LDL-P in
HART-D.
While minimal effects were seen regarding median based discordance and exercise
induced changes in non-lipoprotein CVD risk factors in HERITAGE, significant within
group changes were observed in both studies. Within HERITAGE, all participants on
average improved cardiorespiratory fitness regardless of HDL and LDL discordance status.
Furthermore, all HDL discordance groups significantly decreased body fat percentage,
while three of four LDL discordance groups in both males and females displayed similar
changes. Within the HART-D study, all exercise groups significantly increased the
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concentration of medium LDL-P, while the combined AT/RT group significantly reduced
HbA1C levels.57 Thus, while discordance status may affect the lipoprotein profile and its
ability to beneficially respond to regular exercise, individuals will still benefit from
exercise regardless of discordance status across a number of clinically relevant phenotypes.
Our study is the first to investigate the relationship between lipoprotein discordance
with exercise induced changes in CVD risk factors, however, multiple studies have
examined the effects of exercise training on lipoprotein subclass profiles. 24, 63-72 The most
common findings in the literature are a decrease in small LDL-P concentration, 24, 63, 65, 67,
71, 72

as well as increases in either large HDL-P or mean HDL-P size.24, 63, 65, 66, 68, 69

Sarzynski et al24 showed that in HERITAGE and five other exercise training studies there
was an overall mean decrease in small LDL-P and increase in large HDL-P concentrations.
In our HERITAGE analysis, these changes were isolated to certain discordance groups,
with some even displaying opposite direction of effects. Thus, lipoprotein discordance may
affect the common beneficial lipoprotein subclass changes associated with exercise
training.
4.1. Strengths and Limitations
Our analysis is strengthened by the fact that we examined data from two large, well
supervised and standardized exercise training studies. Furthermore, adherence in both
studies was very high (>95% in HERITAGE, >70% in HART-D). NMR measures for both
studies were standardized and performed in the same laboratory, thus minimizing
measurement error.
Our study is limited by the fact that HERITAGE did not include a control group.
Thus, risk factor changes could only be assessed relative to baseline levels and changes
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between groups. Analyses were also performed without post hoc correction. Thus, our
results should be interpreted with caution as multiple phenotypes were tested.
4.2. Conclusions
Our analyses found that individuals with High HDL-C and Low LDL-P had more
favorable baseline risk factor profiles, regardless of median based lipoprotein discordance
status. The association of lipoprotein discordance with exercise induced changes in these
risk factors was primarily limited to the specific lipoprotein metrics represented by each
analysis (i.e. HDL subclass measures in HDL discordance analysis) while continuous HDL
discordance was also negatively associated with training induced changes in triglycerides
and small LDL-P concentration. In median based discordance analyses, individuals with
High HDL-P decreased in mean continuous discordance (decreased HDL-C/increased
HDL-P percentiles) while Low HDL-P individuals had opposing responses. Furthermore,
while all but one female LDL discordant group (High LDL-C/Low LDL-P) increased mean
continuous discordance (increased LDL-C/decreased LDL-P percentiles), males with Low
LDL-P decreased in continuous discordance. Conversely, Men with High LDL-P increased
continuous LDL discordance. In continuous discordance analysis, baseline lipoprotein
discordance (both LDL and HDL) were negatively associated with training induced
changes in continuous discordance. Thus, median based and continuous lipoprotein
discordance may differentially associate with training induced changes in CVD risk
factors. Nevertheless, all exercise training resulted in some level of beneficial risk factor
change. Thus, while lipoprotein discordance may predict differential training induced
lipoprotein subclass changes, individuals will still benefit from exercise across multiple
clinically relevant risk factors.
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Table 5.1. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant men in the HERITAGE Family Study
Low HDL-C/
Low HDL-P
N=109
(33.9%)

Low HDL-C/
High HDL-P
N=51
(15.8%)

High HDL-C/
Low HDL-P
N=50
(15.5%)

High HDL-C/
High HDL-P
N=112
(34.8%)

p
value
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Demographics
% White
78.90
66.67
56.00
75.00
0.0173
Continuous HDL Discordance (% difference between HDL-C and
Continuous HDL Discordance
1.62 (1.74)b,c
-44.95 (2.54)*
40.59 (2.57)*
0.76 (1.72)b,c
<.0001
HDL-P)
Cholesterol Measurements, (mg/dL)
Total Cholesterol
167.01 (3.35)b,d
179.03 (4.69)a
172.5 (4.72)
178.89 (3.23)a
0.0342
b,c
a,b
Triglycerides
119.58 (6.3)
208.4 (8.82)*
96.64 (8.88)
108.56 (6.08)b
<.0001
HDL-C
30.82 (0.69)c,d
32.19 (0.97)c,d
40.5 (0.98)*
44.31 (0.67)*
<.0001
LDL-C
117.93 (2.95)
109.38 (4.13)
118.46 (4.16)
118.76 (2.85)
0.2556
Lipoprotein Particle Size (nm)
HDL-P size
8.71 (0.04)*
8.99 (0.05)a,c
9.16 (0.05)a,b
9.06 (0.03)a
<.0001
a,b
LDL-P size
20.57 (0.05)*
20.19 (0.07)*
21.09 (0.07)
20.95 (0.05)a,b
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
24.88 (0.29)*
31.72 (0.41)a,c
26.88 (0.41)*
32.37 (0.28)a,c
<.0001
b,c
b,c
Small HDL-P
16.58 (0.35)
18.62 (0.49)*
14.59 (0.49)*
16.57 (0.34)
<.0001
Medium HDL-P
5.93 (0.34)*
9.89 (0.47)*
7.96 (0.47)*
11.23 (0.32)*
<.0001
Large HDL-P
2.38 (0.14)*
3.21 (0.20)*
4.34 (0.20)a,b
4.56 (0.14)a,b
<.0001
c,d
a
a
LDL-P
1100.01 (27.67)
1049.25 (38.74) 951.87 (39.01)
1017.74 (26.71)
0.0134
Small LDL-P
670.96 (24.40)* 780.24 (34.16)* 444.18 (34.40)a,b 506.21 (23.55)a,b
<.0001
Large LDL-P
298.79 (16.58)b,d
140.2 (23.22)*
349.72 (23.38)b
349.55 (16.00)b
<.0001
a
b
c
p<0.05 between low HDL-C/low HDL-P, p<0.05 between low HDL-C/high HDL-P, p<0.05 between high HDL-C/low
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, race,
and baseline body mass index.

Table 5.2. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant women in the HERITAGE Family Study
Low HDL-C/
Low HDL-P
N=131 (33.3%)

Low HDL-C/
High HDL-P
N=63 (16.0%)

High HDL-C/
Low HDL-P
N=66 (16.8%)

High HDL-C/
High HDL-P
N=133 (33.8%)

p
value
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Demographics
% White
50.38
73.02
54.55
66.92
0.0047
Continuous HDL Discordance (% difference between HDL-C and HDL-P)
Continuous HDL Discordance
-1.07 (1.56)b,c
-39.54 (2.24)*
42.65 (2.19)*
-1.36 (1.54)b,c
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
155.76 (2.47)b,d
175.27 (3.71)a,c
158.32 (3.45)b,d
176.26 (2.47)a,c
<.0001
b,c
Triglycerides
90.88 (3.61)
131.35 (5.41)*
66.95 (5.03)*
90.26 (3.60)b,c
<.0001
HDL-C
35.71 (0.54)*
37.9 (0.81)*
49.67 (0.75)*
52.65 (0.54)*
<.0001
LDL-C
107.89 (2.29)b
118.69 (3.43)a,c
101.4 (3.19)b,d
113.06 (2.28)c
0.002
Lipoprotein Particle Size
HDL-P size
(nm)
9.07 (0.03)c,d
9.06 (0.04)c,d
9.80 (0.04)*
9.51 (0.03)*
<.0001
c,d
LDL-P size
20.89 (0.04)
20.74 (0.07)c,d
21.25 (0.06)a,b
21.21 (0.04)a,b
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
25.73 (0.28)b,d
32.42 (0.42)*
26.51 (0.39)b,d
34.93 (0.28)*
<.0001
b,c
b,c
Small HDL-P
13.87 (0.37)
16.29 (0.56)*
10.78 (0.52)*
13.93 (0.37)
<.0001
Medium HDL-P
7.98 (0.38)b,d
11.79 (0.56)*
8.46 (0.52)b,d
13.69 (0.37)*
<.0001
Large HDL-P
3.88 (0.16)c,d
4.34 (0.24)c,d
7.27 (0.22)a,b
7.31 (0.16)a,b
<.0001
b,c
b,c
Total LDL-P
927.14 (22.81)
1122.52 (34.21)* 743.42 (31.83)*
905.7 (22.79)
<.0001
Small LDL-P
480.47 (16.86)*
636.32 (25.28)*
267.34 (23.52)*
371.51 (16.84)*
<.0001
d
d
a,b
Large LDL-P
317.55 (15.08)
326.27 (22.62)
354.16 (21.04)
382.96 (15.07)
0.017
a
p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low HDLP, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was assessed via
assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age,
race, and baseline body mass index.

Table 5.3. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the
HERITAGE Family Study
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Low HDL-C/ Low HDL-C/ High HDL-C/ High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
High HDL-P
N=109
N=51
N=50
N=112
p
(33.9%)
(15.8%)
(15.5%)
(34.8%)
value
Anthropometrics (Baseline measurements not adjusted for baseline BMI)
BMI (kg/m2)
28.06 (0.47)c,d 28.62 (0.66)c,d 25.39 (0.67)a,b 26.38 (0.46)a,b 0.0004
Body Fat (%)
24.10 (0.79)c
25.91 (1.11)c,d 21.11 (1.09)a,b
22.29 (0.77)b
0.0063
2
c,d
c,d
a,b
Visceral abdominal Fat (cm )
106.05 (4.88)
113.86 (6.81)
84.78 (6.87)
85.87 (4.73)a,b 0.0003
Cardiorespiratory Fitness (ml/kg/min)
VO2max
34.96 (0.48)
34.72 (0.68)
34.58 (0.69)
35.27 (0.47)
0.822
Blood Pressure (mmHg)
Systolic blood pressure
121.45 (1.05)
124.32 (1.49)
122.92 (1.49)
121.86 (1.02)
0.3872
Diastolic blood pressure
69.45 (0.78)
72.81 (1.11)
71.40 (1.10)
70.68 (0.76)
0.0699
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
5.32 (0.06)
5.25 (0.08)
5.18 (0.08)
5.19 (0.06)
0.2979
Insulin (pmol/L)
77.24 (4.85)
84.21 (6.94)
70.90 (6.80)
65.29 (4.66)
0.0884
Insulin Sensitivity (μU/min/mL)
3.03 (0.24)d
2.77 (0.34)d
3.07 (0.34)d
3.94 (0.23)*
0.0058
Hepatic Lipase (nmol/mL/min)
217.40 (6.16)
225.80 (8.97)
204.24 (8.97)
209.91 (5.95)
0.3027
c,d
c,d
a,b
a,b
Lipoprotein Lipase (nmol/mL/min)
52.88 (2.70)
44.85 (3.94)
63.91 (3.94)
66.17 (2.61)
<.0001
Inflammatory Markers
GlycA (µmol/L)
307.85 (4.71)
324.89 (6.60)
301.16 (6.65)
313.94 (4.55)
0.0624
C-Reactive Protein (mg/dL)
0.21 (0.02)
0.15 (0.03)
0.17 (0.03)
0.20 (0.02)
0.2912
a
b
c
p<0.05 between low HDL-C/low HDL-P, p<0.05 between low HDL-C/high HDL-P, p<0.05 between high HDLC/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and
baseline body mass index.

Table 5.4. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant Women in the HERITAGE
Family Study
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Low HDL-C/
Low HDL-C/ High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
N=131
N=63
N=66
(33.3%)
(16.0%)
(16.8%)
Anthropometrics (Baseline measurements not adjusted for baseline BMI)
BMI (kg/m2)
27.15 (0.42)*
29.19 (0.62)*
24.61 (0.59)a,b
Body Fat (%)
34.80 (0.73)c,d
36.41 (1.11)c,d 29.29 (1.01)a,b
Visceral abdominal Fat (cm2)
79.34 (3.08)*
101.89 (4.47)* 55.58 (4.21)a,b
Cardiorespiratory Fitness (ml/kg/min)
VO2max
26.47 (0.36)d
27.1 (0.54)
27.15 (0.5)
Blood Pressure (mmHg)
Systolic blood pressure
117.61 (0.96)
118.77 (1.43)
114.65 (1.35)
Diastolic blood pressure
68.67 (0.64)
67.89 (0.95)
66.62 (0.89)
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
5.03 (0.05)b,d
5.25 (0.07)*
4.91 (0.07)b
Insulin (pmol/L)
73.58 (3.84)c
83.06 (5.80)c,d 60.57 (5.37)a,b
c,d
Insulin Sensitivity (μU/min/mL)
3.36 (0.25)
3.24 (0.36)c,d
4.41 (0.34)a,b
134.75
Hepatic Lipase (nmol/mL/min)
171.59 (5.06)c,d 165.69 (7.42)c,d
a,b a,b
c,d
c,d
(7.06)
Lipoprotein Lipase (nmol/mL/min)
54.8 (2.72)
50.69 (3.99)
86.18
(3.79)
Inflammatory Markers
GlycA (µmol/L)
327.21 (4.34)* 361.61 (6.51)a,c 308.26 (6.06)*
C-Reactive Protein (mg/dL)
0.26 (0.05)d
0.42 (0.08)
0.25 (0.08)d
a

High HDL-C/
High HDL-P
N=133
(33.8%)

p
value

25.39 (0.43)a,b
30.76 (0.74)a,b
61.99 (3.03)a,b

<.0001
<.0001
<.0001

27.91 (0.35)a

0.0484

118.86 (0.95)
68.52 (0.63)

0.0767
0.2448

4.83 (0.05)a,b
65.59 (3.85)b
4.4 (0.25)a,b
135.33 (5.07)a,b
80.05 (2.72)a,b

<.0001
0.0178
0.0029
<.0001
<.0001

348.99 (4.36)a,c
0.47 (0.05)a,c

<.0001
0.0144

p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline body mass
index.

Table 5.5. Delta Lipoprotein subclass outcomes for HDL discordant/concordant men in the HERITAGE Family Study
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Low HDL-C/
Low HDL-C/ High HDL-C/ High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
High HDL-P
N=109
N=51
N=50
N=112
p
(33.9%)
(15.8%)
(15.5%)
(34.8%)
value
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)
Continuous HDL Discordance
3.20 (2.41)b,c
-19.49 (3.48)* 17.89 (3.55)*
-2.38 (2.33)b,c
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
-1.92 (1.65)d
-2.78 (2.24)d
2.74 (2.29)
2.91 (1.54)a,b
0.0491
Triglycerides
-7.75 (4.24)
-9.74 (6.38)
-1.06 (6.04)
-3.25 (4.06)
0.6911
HDL-C
1.27 (0.45)
1.02 (0.57)
1.14 (0.58)
1.25 (0.45)
0.9819
LDL-C
-2.21 (1.46)
-0.50 (2.01)
1.81 (2.04)
1.11 (1.37)
0.2622
Lipoprotein Particle Size (nm)
HDL-P size
-0.06 (0.03)c,d
-0.1 (0.03)c,d
0.09 (0.04)a,b
0.04 (0.02)a,b
0.0001
c,d
c,d
a,b
a,b
LDL-P size
-0.05 (0.04)
-0.1 (0.06)
0.12 (0.06)
0.13 (0.04)
0.0044
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
-1.09 (0.37)c,d
-1.13 (0.44)c,d
0.29 (0.43)a,b
0.71 (0.34)a,b
0.0001
Small HDL-P
0.17 (0.32)
0.44 (0.46)
-0.86 (0.47)
-0.10 (0.31)
0.2324
c,d
d
a
a,b
Medium HDL-P
-1.61 (0.40)
-0.83 (0.50)
0.13 (0.50)
0.74 (0.36)
0.0002
Large HDL-P
-0.17 (0.12)c,d
-0.39 (0.16)c,d
0.57 (0.16)a,b
0.42 (0.12)a,b
<.0001
LDL-P
-22.65 (15.68)
23.47 (21.82)
20.81 (22.15)
-2.63 (15.06)
0.221
Small LDL-P
-18.70 (16.60)
16.49 (23.90) -24.92 (23.90) -47.38 (16.26)
0.1793
Large LDL-P
13.57 (13.04)
11.54 (19.41)
49.83 (18.55)
36.38 (12.84)
0.3104
a
b
c
p<0.05 between low HDL-C/low HDL-P, p<0.05 between low HDL-C/high HDL-P, p<0.05 between high HDLC/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C).

Table 5.6. Delta Lipoprotein subclass outcomes for HDL discordant/concordant Women in the HERITAGE Family Study
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Low HDL-C/
Low HDL-C/
High HDL-C/
High HDL-C/
Low HDL-P
High HDL-P
Low HDL-P
High HDL-P
N=131
N=63
N=66
N=133
p
(33.3%)
(16.0%)
(16.8%)
(33.8%)
value
Continuous HDL Discordance (% difference between HDL-C and HDL-P)
Continuous HDL Discordance
4.35 (2.21)*
-19.98 (3.12)*
21.5 (3.04)*
-5.26 (2.14)*
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
1.51 (1.5)
3.27 (2.14)
2.60 (2.00)
2.71 (1.44)
0.9072
Triglycerides
-1.84 (2.71)
3.64 (4.15)
1.09 (3.83)
-2.58 (2.63)
0.5265
HDL-C
1.54 (0.61)
0.84 (0.75)
3.01 (0.70)
1.74 (0.60)
0.2256
LDL-C
0.16 (1.26)
1.63 (1.86)
-0.53 (1.74)
1.21 (1.23)
0.8013
Lipoprotein Particle Size (nm)
HDL-P size
0.03 (0.02)b
-0.07 (0.03)*
0.08 (0.04)b
0.04 (0.02)b
0.0303
b
b
b
LDL-P size
0.01 (0.04)
-0.17 (0.06)*
0.12 (0.05)
0.03 (0.04)
0.0027
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
-0.94 (0.40)c,d
-0.59 (0.48)d
0.56 (0.48)a
0.65 (0.41)a,b
0.006
Small HDL-P
-0.30 (0.33)
0.5 (0.51)
-0.51 (0.48)
-0.28 (0.33)
0.5166
d
d
a,c
Medium HDL-P
-1.21 (0.38)
-0.15 (0.54)
-0.93 (0.51)
0.98 (0.38)
0.0019
Large HDL-P
0.21 (0.14)c
-0.1 (0.19)c,d
0.74 (0.18)a,b
0.38 (0.14)b
0.0265
LDL-P
-6.42 (15.15)
39.62 (23.65)
-9.54 (22.01)
22.17 (15.15)
0.2921
b
b,d
b,c
Small LDL-P
-11.7 (15.04)
78.95 (24.06)* -62.76 (22.17)
-7.25 (15.2)
0.001
Large LDL-P
14.46 (11.09)
7.52 (16.56)
34.36 (15.4)
39.59 (11.11)
0.2569
a
b
c
p<0.05 between low HDL-C/low HDL-P, p<0.05 between low HDL-C/high HDL-P, p<0.05 between high HDLC/low HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C).

Table 5.7. Delta cardiovascular disease risk factor outcomes for HDL discordant/concordant men in the HERITAGE
Family Study
Low HDL-C/
Low HDL-P
N=109
(33.9%)

Low HDL-C/
High HDL-P
N=51
(15.8%)

High HDL-C/
Low HDL-P
N=50
(15.5%)

High HDL-C/
High HDL-P
N=112
(34.8%)

p
value

82

Anthropometrics
BMI (kg/m2)
-0.22 (0.08)
-0.31 (0.11)
-0.1 (0.11)
-0.11 (0.07)
0.4006
Body Fat (%)
-1.08 (0.19)
-0.68 (0.26)
-1.12 (0.25)
-0.8 (0.18)
0.4297
2
Visceral abdominal Fat (cm )
-10.08 (1.71)
-6.96 (2.31)
-9.12 (2.37)
-7.12 (1.63)
0.512
Cardiorespiratory Fitness (ml/kg/min)
VO2max
5.06 (0.3)
4.60 (0.41)
5.35 (0.42)
5.72 (0.28)
0.1057
Blood Pressure (mmHg)
Systolic blood pressure
-1.50 (0.69)
-0.20 (0.95)
0.44 (0.95)
-1.06 (0.64)
0.3326
c,d
c,d
a,b
a,b
Diastolic blood pressure
-0.90 (0.57)
-1.38 (0.79)
1.28 (0.79)
0.87 (0.54)
0.0122
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
0.11 (0.04)b
-0.05 (0.06)a,d
-0.02 (0.06)
0.11 (0.04)b
0.0423
Insulin (pmol/L)
-6.77 (2.49)
-7.78 (3.45)
-13.18 (3.56)
-7.10 (2.35)
0.4751
Insulin Sensitivity (μU/min/mL)
0.49 (0.24)
0.36 (0.33)
-0.07 (0.34)
0.28 (0.22)
0.5815
Hepatic Lipase (nmol/mL/min)
-6.06 (4.53)c,d
-18.04 (6.41)c -37.02 (6.53)a,b -22.35 (4.34)a
0.0008
Lipoprotein Lipase (nmol/mL/min)
7.82 (2.34)
5.32 (3.35)
17.07 (3.38)
11.89 (2.3)
0.0632
Inflammatory Markers
GlycA (µmol/L)
-8.47 (3.5)
-4.70 (4.92)
0.18 (4.95)
-7.95 (3.37)
0.4741
d
d
a,b
C'-Reactive Protein (mg/dL)
0.06 (0.02)
0.07 (0.03)
0.04 (0.03)
-0.02 (0.02)
0.0436
a
p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta GlycA adjusted for baseline GlycA

Table 5.8. Delta cardiovascular disease risk factor outcomes for HDL discordant/concordant women in the HERITAGE
Family Study
Low HDL-C/
Low HDL-P
N=131
(33.3%)

Low HDL-C/
High HDL-P
N=63
(16.0%)

High HDL-C/
Low HDL-P
N=66
(16.8%)

High HDL-C/
High HDL-P
N=133
(33.8%)

p
value

83

Anthropometrics
BMI (kg/m2)
-0.13 (0.08)
-0.08 (0.12)
-0.03 (0.11)
-0.09 (0.08)
0.9322
Body Fat (%)
-0.68 (0.2)
-0.71 (0.29)
-0.74 (0.26)
-0.75 (0.19)
0.9943
2
Visceral abdominal Fat (cm )
-2.39 (1.2)
-2.59 (1.77)
-4.71 (1.62)
-5.02 (1.15)
0.3767
Cardiorespiratory Fitness (ml/kg/min)
VO2max
4.92 (0.25)
4.95 (0.36)
5.49 (0.33)
4.96 (0.24)
0.5356
Blood Pressure (mmHg)
Systolic blood pressure
0.54 (0.61)
-1.47 (0.9)
0.38 (0.84)
-0.1 (0.6)
0.3078
Diastolic blood pressure
0.32 (0.49)
0.51 (0.72)
0.62 (0.67)
0.56 (0.48)
0.9803
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
0.15 (0.04)
0.18 (0.06)
0.08 (0.06)
0.02 (0.04)
0.0674
c
c
a,b
Insulin (pmol/L)
-3.94 (2.25)
-3.25 (3.33)
-13.02 (3.1)
-9.67 (2.23)
0.0492
Insulin Sensitivity (μU/min/mL)
0.17 (0.21)
-0.17 (0.3)
-0.04 (0.29)
0.11 (0.21)
0.7759
Hepatic Lipase (nmol/mL/min)
-8.12 (3.67)
-0.39 (5.32)
-13.9 (4.96)
-10.17 (3.67)
0.3211
c,d
c,d
a,b
a,b
Lipoprotein Lipase (nmol/mL/min)
2.73 (2.39)
-3.64 (3.48)
12.32 (3.25)
11.09 (2.36)
0.0017
Inflammatory Markers
GlycA (µmol/L)
-6.22 (3.33)
-0.72 (5.06)
-6.00 (4.74)
1.30 (3.36)
0.4241
b
b
b
C-Reactive Protein (mg/dL)
-0.07 (0.04)
0.17 (0.06)*
-0.10 (0.06)
0.00 (0.04)
0.0035
a p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low
HDL-P, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta GlycA adjusted for baseline GlycA).

Table 5.9. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant men in the HERITAGE Family Study
Low LDL-C/
Low LDL-P
N=133
(41.3%)

Low LDL-C/
High LDL-P
N=28
(8.7%)

High LDL-C/
Low LDL-P
N=23
(7.1%)

High LDL-C/
High LDL-P
N=138
(42.9%)

p
value

84

Demographics
% White
71.43
60.87
67.86
75.36
0.4845
Continuous LDL Discordance (% difference between LDL-C and LDL-P)
Continuous LDL Discordance
0.11 (1.06)b,c
-25.26 (2.56)*
22.31 (2.32)*
-0.43 (1.04)b,c
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
144.72 (2.30)*
169.55 (4.93)a,d
181.95 (4.44)a,d
202.53 (2.26)*
<.0001
b,d
a,c
Triglycerides
111.83 (6.76)
149.39 (14.50)
100.17 (13.07)b,d
142.87 (6.66)a,c
0.0013
d
d
b,c
HDL-C
37.43 (0.87)
40.60 (1.87)
40.29 (1.68)
36.1 (0.86)
0.0356
LDL-C
89.92 (1.79)*
103.3 (3.85)*
127.1 (3.47)*
144.15 (1.77)*
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
9.07 (0.04)d
9.02 (0.08)d
9.07 (0.07)d
8.81 (0.04)*
<.0001
b,c
a,b
LDL-P size
20.74 (0.06)
20.48 (0.12)
21.16 (0.11)*
20.66 (0.05)c
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
29.07 (0.43)b
31.31 (0.91)*
28.68 (0.82)b
28.42 (0.42)b
0.032
Small HDL-P
16.04 (0.35)
17.54 (0.74)
15.87 (0.67)
17.04 (0.34)
0.0936
Medium HDL-P
9.05 (0.39)
9.85 (0.83)
8.8 (0.75)
8.27 (0.38)
0.2487
Large HDL-P
3.97 (0.16)d
3.93 (0.35)d
4.00 (0.31)d
3.11 (0.16)*
0.0007
LDL-P
774.18 (17.14)* 1110.03 (36.75)* 957.63 (33.12)* 1302.19 (16.87)* <.0001
Small LDL-P
451.88 (22.39)b,d 698.27 (47.99)a,c 424.14 (43.25)b,d
749.1 (22.03)a,c
<.0001
c,d
d
a
a,b
Large LDL-P
222.71 (16.21)
280.74 (34.75)
369.13 (31.32)
362.30 (15.95)
<.0001
a
p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age,
race, and baseline body mass index

Table 5.10. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant women in the HERITAGE Family Study
Low LDL-C/
Low LDL-P
N=160
(40.7%)

Low LDL-C/
High LDL-P
N=35
(8.9%)

High LDL-C/
Low LDL-P
N=36
(9.1%)

High LDL-C/
High LDL-P
N=162
(41.2%)

p
value

85

Demographics
% White
60.63
42.86
50.00
66.05
0.0404
Continuous LDL Discordance (% difference between LDL-C and LDL-P)
Continuous LDL Discordance
0.27 (0.97)b,c
-26.76 (2.08)*
26.83 (2.05)*
-0.47 (0.97)b,c
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
141.35 (1.67)*
153.71 (3.37)*
180.49 (3.34)*
190.66 (1.69)*
<.0001
Triglycerides
75.80 (3.41)b,d
120.63 (6.88)a,c
75.36 (6.81)b,d
107.10 (3.45)a,c <.0001
HDL-C
45.72 (0.76)*
37.95 (1.54)*
50.1 (1.53)*
42.58 (0.77)*
<.0001
LDL-C
86.20 (1.35)*
99.60 (2.73)*
121.62 (2.71)*
134.34 (1.37)*
<.0001
Lipoprotein Particle Size (nm)
HDL-P size
9.48 (0.03)*
9.03 (0.06)*
9.72 (0.06)*
9.18 (0.03)*
<.0001
LDL-P size
20.94 (0.04)*
20.65 (0.08)*
21.57 (0.08)*
21.1 (0.04)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
29.37 (0.41)
30.08 (0.83)
29.16 (0.83)
30.69 (0.42)
0.1264
b,c
a,c
c
Small HDL-P
13.38 (0.36)
15.13 (0.72)
11.17 (0.72)*
14.33 (0.36)
0.0002
Medium HDL-P
9.78 (0.40)
10.59 (0.81)
10.48 (0.80)
11.34 (0.40)
0.0728
Large HDL-P
6.21 (0.18)*
4.35 (0.37)a,c
7.52 (0.37)*
5.03 (0.19)a,c
<.0001
LDL-P
674 (14.80)*
1004.55 (29.87)*
804.2 (29.57)*
1173.41 (14.97)* <.0001
Small LDL-P
338.09 (15.52)*
571.40 (31.32)a,c
219.28 (31.01)*
542.04 (15.70)a,c <.0001
Large LDL-P
235.67 (11.99)*
315.92 (24.21)*
415.97 (23.97)a,b 452.61 (12.14)a,b <.0001
a
b
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. Continuous discordance was
assessed via assessed via univariable regression analyses. Unless otherwise noted, all other models were adjusted for age, race,
and baseline body mass index.

Table 5.11. Baseline cardiovascular disease risk factor outcomes for LDL discordant/concordant men in the HERITAGE Family
Study
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Low LDL-C/
Low LDL-C/ High LDL-C/ High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
N=133
N=28
N=23
N=138
p
(41.3%)
(8.7%)
(7.1%)
(42.9%)
value
Anthropometrics (Baseline measurements not adjusted for baseline BMI)
BMI (kg/m2)
25.08 (0.43)b,d
29.35 (0.93)* 26.32 (0.85)b,d 28.82 (0.42)a,c
<.0001
b,d
b,d
a,c
Body Fat (%)
19.66 (0.70)
27.21 (1.61)* 21.90 (1.36)
26.23 (0.67)
<.0001
2
b,d
a
d
a,c
Visceral abdominal Fat (cm )
82.61 (4.55)
108.15 (9.92)
89.55 (9.02)
109.90 (4.48)
0.0002
Cardiorespiratory Fitness (ml/kg/min)
VO2max
36.18 (0.46)d
34.41 (0.98)
34.87 (0.86)
33.89 (0.45)a
0.0069
Blood Pressure (mmHg)
Systolic blood pressure
123.68 (1)
119.9 (2.15)
119.64 (1.93)
122.04 (0.99)
0.1661
Diastolic blood pressure
71.48 (0.75)
68.78 (1.61)
69.06 (1.45)
70.85 (0.74)
0.2726
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
5.26 (0.06)
5.22 (0.12)
5.13 (0.11)
5.24 (0.05)
0.735
Insulin (pmol/L)
75.87 (4.73)
71.97 (10)
65.31 (8.8)
72.31 (4.63)
0.7542
Insulin Sensitivity (μU/min/mL)
3.38 (0.24)
2.57 (0.5)
3.20 (0.47)
3.40 (0.23)
0.4613
Hepatic Lipase (nmol/mL/min)
222.31 (5.88) 190.31 (12.74) 204.56 (11.5)
211.52 (5.85)
0.1049
Lipoprotein Lipase (nmol/mL/min)
56.74 (2.68)
64.10 (5.81)
68.52 (5.24)
56.40 (2.66)
0.1157
Inflammatory Markers
GlycA (µmol/L)
302.00 (4.40)b,d 348.11 (9.44)* 303.00 (8.51)b 316.03 (4.33)a,b 0.0002
C-Reactive Protein (mg/dL)
0.18 (0.02)
0.25 (0.04)
0.13 (0.04)
0.19 (0.02)
0.2665
a
b
c
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, p<0.05 between high LDLC/low LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline
body mass index.

Table 5.12. Baseline cardiovascular disease outcomes for LDL discordant/concordant Women in the HERITAGE
Family Study
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Low LDL-C/
Low LDL-C/
High LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
N=160
N=35
N=36
N=162
p
(40.7%)
(8.9%)
(9.1%)
(41.2%)
value
Anthropometrics (Baseline measurements not adjusted for baseline BMI)
BMI (kg/m2)
25.16 (0.40)b,d
27.20 (0.81)a,c
24.59 (0.80)b,d
27.99 (0.40)a,c <.0001
Body Fat (%)
30.95 (0.70)d
33.32 (1.46)
29.58 (1.44)d
35.09 (0.70)a,c <.0001
2
b,d
a,c
b,d
Visceral abdominal Fat (cm )
61.77 (2.98)
75.79 (5.96)
57.49 (5.89)
86.76 (2.94)a,c <.0001
Cardiorespiratory Fitness (ml/kg/min)
VO2max
27.09 (0.33)
27.9 (0.66)
28.27 (0.67)
26.8 (0.34)
0.1595
Blood Pressure (mmHg)
Systolic blood pressure
117.19 (0.89)
118.59 (1.80)
113.75 (1.83)
118.94 (0.90)
0.0721
Diastolic blood pressure
67.32 (0.59)
68.34 (1.19)
68.40 (1.21)
68.92 (0.6)
0.3316
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
4.95 (0.05)
5.14 (0.09)
4.93 (0.09)
4.97 (0.05)
0.2842
Fasting insulin (pmol/L)
72.33 (3.62)
69.19 (7.4)
59.69 (7.22)
70.33 (3.69)
0.4837
Insulin Sensitivity (μU/min/mL)
4.32 (0.23)d
4.88 (0.46)d
4.13 (0.44)d
3.08 (0.23)*
0.0002
d
d
a,b
Hepatic Lipase (nmol/mL/min)
157.68 (4.84)
167.05 (9.68)
160.16 (9.72)
140.75 (4.97)
0.0267
c,d
b
b
Lipoprotein Lipase (nmol/mL/min)
66.48 (2.76)
55.93 (5.51)
77.06 (5.53)
70.34 (2.83)
0.0404
Inflammatory Markers
GlycA (µmol/L)
324.08 (4.14)b,d 350.82 (8.35)a,c 317.31 (8.27)b,d 350.07 (4.21)a,c <.0001
C-Reactive Protein (mg/dL)
0.28 (0.05)b
0.61 (0.10)*
0.26 (0.10)b
0.39 (0.05)b
0.0162
a
b
c
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, and baseline
body mass index.

Table 5.13. Delta Lipoprotein subclass outcomes for LDL discordant/concordant men in the HERITAGE Family Study
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Low LDL-C/
Low LDL-C/
High LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
N=133
N=28
N=23
N=138
p
(41.3%)
(8.7%)
(7.1%)
(42.9%)
value
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)
Continuous LDL Discordance
-0.8 (1.15)b,c
15.07 (2.8)*
-10 (2.49)*
0.04 (1.14)b,c
<.0001
Cholesterol Measurements, (mg/dL)
Total Cholesterol
-0.62 (1.92)
2.48 (3.34)
3.38 (2.96)
0.49 (1.85)
0.6318
Triglycerides
-4.65 (3.98)
-15.92 (8.49)
8.78 (7.55)
-7.15 (3.9)
0.1623
HDL-C
1.39 (0.38)
1.27 (0.82)
0.24 (0.72)
1.19 (0.37)
0.5503
LDL-C
-2.47 (1.8)
2.91 (3.01)
1.54 (2.64)
1.44 (1.76)
0.3272
Lipoprotein Particle Size (nm)
HDL-P size
0.04 (0.02)
-0.02 (0.05)
0 (0.05)
-0.06 (0.02)
0.082
LDL-P size
-0.03 (0.04)
0.07 (0.09)
0.11 (0.08)
0.06 (0.04)
0.2648
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
-0.3 (0.29)
-0.82 (0.62)
-0.21 (0.56)
-0.04 (0.28)
0.6867
Small HDL-P
-0.36 (0.31)
-0.1 (0.66)
-0.2 (0.6)
0.27 (0.3)
0.5597
Medium HDL-P
-0.24 (0.35)
-0.77 (0.74)
-0.5 (0.67)
-0.28 (0.34)
0.9142
Large HDL-P
0.19 (0.11)
0.31 (0.24)
0.31 (0.21)
-0.05 (0.11)
0.2274
c
c,d
a,b
b
LDL-P
-24.83 (19.48)
-71.96 (31.63)
45.08 (28.65)
27.31 (19.02)
0.0087
Small LDL-P
-28.26 (16.73)
-80.65 (33.73)
-30.96 (31.03)
-6.03 (16.39)
0.2164
c,d
a
a
Large LDL-P
-15.12 (12.43)
35.51 (25.94)
79.14 (23.6)
58.1 (12.27)
0.0002
a
b
c
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C).

Table 5.14. Delta Lipoprotein subclass outcomes for LDL discordant/concordant women in the HERITAGE Family Study
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Low LDL-C/
Low LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
N=160
N=35
N=36
(40.7%)
(8.9%)
(9.1%)
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)
Continuous LDL Discordance
0.32 (1.24)b,c
7.02 (2.63)*
-11.48 (2.59)*
Cholesterol Measurements, (mg/dL)
Total Cholesterol
2.88 (1.71)
2.17 (2.74)
-1.36 (2.70)
d
Triglycerides
-3.79 (2.58)
-3.42 (5.02)
-9.79 (4.95)d
HDL-C
2.2 (0.45)
0.87 (0.91)
1.92 (0.9)
LDL-C
0.51 (1.59)
0.52 (2.38)
-1.36 (2.34)
Lipoprotein Particle Size (nm)
HDL-P size
0.04 (0.02)
-0.01 (0.04)
0.05 (0.04)
LDL-P size
0.03 (0.03)
-0.14 (0.07)
0.09 (0.07)
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
HDL-P
0.16 (0.29)
-0.33 (0.59)
0.19 (0.59)
Small HDL-P
-0.23 (0.31)
0.14 (0.63)
-0.47 (0.63)
Medium HDL-P
-0.27 (0.34)
-0.19 (0.69)
-0.77 (0.68)
Large HDL-P
0.30 (0.11)
0.15 (0.23)
0.59 (0.23)
LDL-P
-12.44 (18.63)
2.41 (28.77)
44.74 (28.84)
b,d
a
Small LDL-P
-44.88 (14.72)
45.20 (28.89)
1.20 (29.69)
d
c,d
Large LDL-P
9.05 (11.27)
-17.60 (20.66)
47.89 (20.63)b
a

High LDL-C/
High LDL-P
N=162
(41.2%)

p
value

0.70 (1.21)b,c

<.0001

2.88 (1.62)
4.96 (2.48)a,c
1.51 (0.44)
1.23 (1.52)

0.5261
0.0218
0.5547
0.8093

0.01 (0.02)
0 (0.03)

0.6284
0.1264

-0.33 (0.3)
-0.21 (0.32)
-0.10 (0.34)
0.30 (0.12)
24.36 (18.6)
21.05 (14.93)a
46.94 (11.30)a,b

0.6464
0.9255
0.8588
0.5934
0.3127
0.009
0.0232

p<0.05 between low LDL-C/low LDL-P, b p<0.05 between low LDL-C/high LDL-P, c p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta HDL-C adjusted for baseline HDL-C).

Table 5.15. Delta cardiovascular disease outcomes for LDL discordant/concordant men in the HERITAGE Family Study
Low LDL-C/
Low LDL-P
N=133
(41.3%)

Low LDL-C/
High LDL-P
N=28
(8.7%)

High LDL-C/
Low LDL-P
N=23
(7.1%)

High LDL-C/
High LDL-P
N=138
(42.9%)

p
value
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Anthropometrics
BMI (kg/m2)
-0.24 (0.07)
-0.19 (0.16)
-0.14 (0.14)
-0.12 (0.07)
0.684
Body Fat (%)
-1.13 (0.18)
-0.72 (0.4)
-1.09 (0.32)
-0.71 (0.17)
0.3853
Visceral abdominal Fat (cm2)
-8.13 (1.60)
-7.40 (3.42)
-6.43 (3.01)
-9.19 (1.57)
0.8455
Cardiorespiratory Fitness (ml/kg/min)
VO2max
5.43 (0.28)
4.61 (0.60)
6.05 (0.52)
5.04 (0.29)
0.2349
Blood Pressure (mmHg)
Systolic blood pressure
-0.62 (0.64)
-0.01 (1.38)
-0.52 (1.22)
-1.13 (0.64)
0.8593
Diastolic blood pressure
0.57 (0.54)
0.26 (1.15)
0.21 (1.04)
-0.60 (0.54)
0.4895
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
0.01 (0.04)
0.11 (0.09)
0.16 (0.08)
0.09 (0.04)
0.2978
Insulin (pmol/L)
-7.94 (2.36)
-6.65 (4.97)
-6.58 (4.55)
-9.10 (2.33)
0.9376
Insulin Sensitivity (μU/min/mL)
0.49 (0.23)
-0.05 (0.47)
0.90 (0.43)
0.07 (0.21)
0.2461
Hepatic Lipase (nmol/mL/min)
-18.57 (4.39)
-13.32 (9.57)
-24.43 (8.54)
-19.60 (4.44)
0.8456
Lipoprotein Lipase (nmol/mL/min)
10.97 (2.23)
15.14 (4.82)
5.96 (4.37)
9.84 (2.23)
0.5305
Inflammatory Markers
GlycA (µmol/L)
-4.21 (3.36)
-11.63 (7.31)
-3.86 (6.46)
-7.38 (3.29)
0.7911
C-Reactive Protein (mg/dL)
0.03 (0.02)
0.03 (0.05)
0.05 (0.04)
0.03 (0.02)
0.9473
a
b
c
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta GlycA adjusted for baseline GlycA).

Table 5.16. Delta cardiovascular disease outcomes for LDL discordant/concordant women in the HERITAGE Family Study
Low LDL-C/
Low LDL-P
N=160
(40.7%)

Low LDL-C/
High LDL-P
N=35
(8.9%)

High LDL-C/
Low LDL-P
N=36
(9.1%)

High LDL-C/
High LDL-P
N=162
(41.2%)

p
value
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Anthropometrics
BMI (kg/m2)
-0.02 (0.08)
-0.02 (0.15)
-0.19 (0.15)
-0.15 (0.08)
0.5982
Body Fat (%)
-0.73 (0.18)
-1.04 (0.37)
-0.53 (0.36)
-0.68 (0.18)
0.7893
2
Visceral abdominal Fat (cm )
-3.72 (1.1)
-4.27 (2.15)
-8.61 (2.17)
-2.48 (1.09)
0.0963
Cardiorespiratory Fitness (ml/kg/min)
VO2max
5.13 (0.23)
5.37 (0.45)
5.34 (0.45)
4.78 (0.23)
0.4857
Blood Pressure (mmHg)
Systolic blood pressure
0.59 (0.56)
1.28 (1.13)
-0.56 (1.16)
-0.79 (0.57)
0.2198
Diastolic blood pressure
0.98 (0.45)
0.08 (0.9)
0.36 (0.93)
0.09 (0.45)
0.5553
Carbohydrate/Lipid Metabolism
Glucose (mmol/L)
0.1 (0.04)
0.16 (0.07)
-0.02 (0.08)
0.11 (0.04)
0.348
Fasting insulin (pmol/L)
-7.42 (2.1)
-7.62 (4.24)
-13.35 (4.34)
-5.98 (2.1)
0.5048
Insulin Sensitivity (μU/min/mL)
-0.16 (0.19)
0.44 (0.38)
0.01 (0.39)
0.18 (0.2)
0.4512
Hepatic Lipase (nmol/mL/min)
-3.3 (3.3)
-13.11 (6.68)
-12.62 (6.58)
-12.26 (3.46)
0.2306
Lipoprotein Lipase (nmol/mL/min)
5.94 (2.16)
2.70 (4.4)
11.06 (4.34)
6.22 (2.23)
0.6021
Inflammatory Markers
GlycA (µmol/L)
-3.74 (3.13)
-7.05 (6.27)
-0.48 (6.23)
-1.54 (3.19)
0.8409
C-Reactive Protein (mg/dL)
-0.04 (0.04)
-0.09 (0.07)
-0.05 (0.08)
0.04 (0.04)
0.3016
a
b
c
p<0.05 between low LDL-C/low LDL-P, p<0.05 between low LDL-C/high LDL-P, p<0.05 between high LDL-C/low
LDL-P, d p<0.05 between high LDL-C/high LDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). All models were adjusted for age, race, baseline body mass index and
baseline trait (i.e. delta GlycA adjusted for baseline GlycA).

Table 5.17. Baseline Lipoprotein subclass outcomes for HDL discordant/concordant groups in the HART-D study
Low HDL-C/
Low HDL-P
N=80 (37.56%)

Low HDL-C/
High HDL-P
N=26 (12.21%)

High HDL-C/
Low HDL-P
N=28 (13.15%)

High HDL-C/
High HDL-P
N=79 (37.08%)

p
value
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Demographics
% Male
51.25
53.57
15.38
22.78
<.0001
% White
63.75
67.86
38.46
46.84
0.0251
Continuous HDL Discordance (Percentile difference between HDL-C and HDL-P)
Continuous HDL
1.81 (4.80)b,c
-35.77 (5.67)*
36.77 (5.73)*
-2.12 (5.07)b,c
<.0001
Lipid
Panel, (mg/dL)
Discordance
Total Cholesterol
150.74 (9.35)c,d
152.39 (11.05)c
184.27 (11.18)a,b
164.1 (9.88)a
<.0001
d
d
Triglycerides
130.53 (19.24)
141.98 (22.71)
110.36 (22.98)
93.13 (20.31)a,b
0.0011
c,d
c,d
HDL-C
37.47 (2.00)
40.18 (2.36)
51.01 (2.39)*
55.71 (2.11)*
<.0001
LDL-C
87.21 (8.17)c
85.45 (9.66)c
112.83 (9.84)*
90.39 (8.63)c
0.0008
Lipoprotein Particle Size
HDL-P size
8.71 (0.07)*
8.61 (0.08)*
8.96 (0.08)a,b
8.87 (0.07)a,b
<.0001
(nm)
c,d
c,d
LDL-P size
20.54 (0.12)
20.44 (0.14)
21.14 (0.14)*
20.84 (0.12)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
18.86 (0.52)*
22.65 (0.62)*
19.72 (0.63)*
24.03 (0.55)*
<.0001
Small HDL-P
13.36 (0.77)*
17.69 (0.91)*
12.03 (0.92)*
16.02 (0.81)*
<.0001
Medium HDL-P
4.58 (0.56)c,d
3.96 (0.67)c,d
6.23 (0.67)a,b
6.23 (0.60)a,b
<.0001
c,d
c,d
a,b
a,b
Large HDL-P
0.92 (0.22)
1.00 (0.26)
1.46 (0.26)
1.78 (0.23)
<.0001
Total LDL-P
1018.28 (79.63)
1011.75 (94.01)
1093.38 (95.12)
1022.65 (84.07)
0.6322
c,d
c,d
a,b
a,b
Small LDL-P
769.06 (79.86)
830.56 (94.29)
562.53 (95.40)
662.73 (84.32)
0.0007
Medium LDL-P
107.63 (27.75)c
81.66 (32.76)c,d
177.50 (33.15)*
124.47 (29.3)b,c
0.0023
Large LDL-P
141.8 (41.85)c,d
99.72 (49.41)c,d
353.52 (49.99)*
235.49 (44.19)*
<.0001
a
p<0.05 between low HDL-C/low HDL-P, b p<0.05 between low HDL-C/high HDL-P, c p<0.05 between high HDL-C/low HDLP, d p<0.05 between high HDL-C/high HDL-P, * p<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. All models other were adjusted for age,
race, sex, and baseline body mass index.

Table 5.18. Baseline cardiovascular disease risk factor outcomes for HDL discordant/concordant groups in the HART-D study
Low HDL-C/
Low HDL-P
N=80 (37.56%)
Anthropometrics (not adjusted for baseline BMI)
BMI (kg/m2)
33.58 (1.61)
Waist Circumference (cm)
109.44 (3.71)
Body Fat (%)
36.91 (1.38)
Cardiorespiratory Fitness (ml/kg/min)

Low HDL-C/
High HDL-P
N=26 (12.21%)

High HDL-C/
Low HDL-P
N=28 (13.15%)

High HDL-C/
High HDL-P
N=79 (37.08%)

p
value

35.05 (1.90)
113.86 (4.39)
37.06 (1.65)

34.01 (1.93)
110.83 (4.44)
38.36 (1.66)

32.4 (1.70)
106.43 (3.91)
35.90 (1.45)

0.1445
0.0512
0.1197
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VO2max
18.50 (0.81)
18.85 (1.02)
18.28 (1.10)
18.92 (0.90)
0.8007
Blood Pressure (mmHg)
Systolic blood pressure
131.45 (4.02)
132.42 (4.75)
128.26 (4.81)
131.96 (4.25)
0.6433
Diastolic blood pressure
71.58 (2.38)
71.49 (2.82)
71.10 (2.85)
72.70 (2.52)
0.754
Carbohydrate/Lipid Metabolism
Glucose (mg/dL)
142.15 (10.16)
136.26 (11.99)
133.47 (12.14)
139.77 (10.73)
0.6844
c,d
a
a
Insulin (pmol/L)
38.33 (3.77)
34.10 (4.46)
30.10 (4.51)
32.26 (3.98)
0.0095
Hemoglobin A1C (%)
8.10 (0.33)
7.79 (0.39)
7.60 (0.39)
7.87 (0.35)
0.204
Inflammatory Markers
GlycA (µmol/L)
425.23 (17)
442.00 (20.08)
413.92 (20.31)
420.57 (17.95)
0.3107
C-Reactive Protein (mg/L)
5.62 (1.80)
4.15 (2.13)
2.85 (2.15)
4.92 (1.90)
0.232
a
b
c
p<0.05 between low HDL-C/low HDL-P, p<0.05 between low HDL-C/high HDL-P, p<0.05 between high HDL-C/low HDL-P, d p<0.05
between high HDL-C/high HDL-P, * p<0.05 between all other groups

Values are presented as mean (standard error). Demographics were assessed via chi-square. Unless otherwise noted, all models were
adjusted for age, race, sex, and baseline body mass index.

Table 5.19. Baseline Lipoprotein subclass outcomes for LDL discordant/concordant groups in the HART-D study
Low LDL-C/
Low LDL-P
N=81 (38.38%)

Low LDL-C/
High LDL-P
N=24 (11.37%)

High LDL-C/
Low LDL-P
N=22 (10.43%)

High LDL-C/
High LDL-P
N=84 (39.81%)

p
value
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Demographics
% Male
38.27
27.27
37.50
35.71
0.817
% White
45.68
81.82
37.50
60.71
0.0041
Continuous LDL Discordance (Percentile difference between LDL-C and LDL-P)
Continuous LDL
-0.05 (3.94)b,c
-34.44 (4.73)*
28.89 (4.61)*
-0.06 (3.94)b,c
<.0001
Lipid
Panel,
(mg/dL)
Discordance
Total Cholesterol
129.56 (6.90)*
144.41 (8.29)*
166.26 (8.08)*
182.66 (6.90)*
<.0001
Triglycerides
113.74 (18.72)b 146.08 (22.47)a,c 86.62 (21.90)b,d
127.14 (18.72)c
0.0082
HDL-C
42.24 (3.06)c
42.46 (3.67)c
50.70 (3.58)*
42.72 (3.06)c
0.0033
LDL-C
65.03 (5.31)c,d
72.68 (6.37)c,d
100.33 (6.21)*
114.61 (5.31)*
<.0001
Lipoprotein Particle Size
HDL-P size
8.74 (0.07)
8.74 (0.09)
8.89 (0.09)
8.76 (0.07)
0.0539
(nm)
LDL-P size
20.54 (0.13)c,d
20.41 (0.15)c,d
20.97 (0.15)*
20.74 (0.13)*
<.0001
Lipoprotein particle concentrations (HDL: µmol/L; LDL: nmol/L)
Total HDL-P
20.89 (0.87)
21.20 (1.05)
20.60 (1.02)
19.88 (0.87)
0.0882
Small HDL-P
14.44 (0.96)
14.90 (1.15)
13.23 (1.12)
14.05 (0.96)
0.2741
Medium HDL-P
5.32 (0.62)
5.06 (0.75)
5.84 (0.73)
4.69 (0.62)
0.0708
Large HDL-P
1.13 (0.25)
1.26 (0.30)
1.54 (0.29)
1.16 (0.25)
0.1706
LDL-P
796.01 (52.34)* 1094.06 (62.82)* 922.80 (61.24)* 1259.20 (52.33)*
<.0001
Total Small LDL-P
604.41 (71.91)b,d 867.63 (86.31)a,c 527.33 (84.15)b,d 874.57 (71.90)a,c
<.0001
c,d
a
a
Medium LDL-P
82.69 (28.15)
112.70 (33.80)
125.82 (32.95)
146.10 (28.15)
0.0004
Large LDL-P
109.02 (43.50)c,d 113.74 (52.21)c,d 269.86 (50.90)a,b 238.76 (43.50)a,b
<.0001
a
P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDLP, d P<0.05 between high LDL-C/high LDL-P, * P<0.05 between all other groups
Values are presented as mean (standard error). Demographics were assessed via chi-square. All other models were adjusted for age,
race, sex, and baseline body mass index.

Table 5.20. Baseline cardiovascular disease risk factor outcomes for LDL discordant/concordant groups in the HART-D study
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Low LDL-C/
Low LDL-C/
High LDL-C/
High LDL-C/
Low LDL-P
High LDL-P
Low LDL-P
High LDL-P
p
N=81 (38.38%)
N=24 (11.37%)
N=22 (10.43%)
N=84 (39.81%)
value
Anthropometrics (not adjusted for baseline BMI)
BMI (kg/m2)
33.30 (1.66)
34.76 (2.00)
32.89 (1.94)
33.35 (1.66)
0.6806
Waist Circumference (cm)
108.25 (3.84)
112.34 (4.61)
107.79 (4.49)
109.51 (3.84)
0.5739
Body Fat (%)
36.38 (1.41)
37.06 (1.69)
37.54 (1.66)
36.89 (1.41)
0.7224
Cardiorespiratory Fitness (ml/kg/min)
VO2max
18.13 (0.81)
19.22 (1.17)
19.57 (1.07)
18.95 (0.81)
0.2048
Blood Pressure (mmHg)
Systolic blood pressure
130.65 (4.03)
133.17 (4.83)
131.27 (4.71)
131.70 (4.03)
0.8849
Diastolic blood pressure
71.32 (2.43)
71.15 (2.92)
72.73 (2.84)
72.16 (2.43)
0.82
Carbohydrate/Lipid Metabolism
Glucose (mg/dL)
137.04 (10.32)
139.79 (12.39)
136.48 (12.08)
144.53 (10.32)
0.5209
Insulin (pmol/L)
34.03 (3.84)
38.36 (4.61)
34.99 (4.49)
37.65 (3.84)
0.2645
Hemoglobin A1C (%)
7.83 (0.33)
7.89 (0.40)
7.74 (0.39)
8.18 (0.33)
0.1333
Inflammatory Markers
GlycA (µmol/L)
421.80 (17.27)
443.11 (20.73)
402.46 (20.21)
428.50 (17.27)
0.1076
C-Reactive Protein (mg/L)
4.49 (1.85)
6.09 (2.22)
4.75 (2.16)
5.81 (1.85)
0.5012
a
P<0.05 between low LDL-C/low LDL-P, b P<0.05 between low LDL-C/high LDL-P, c P<0.05 between high LDL-C/low LDL-P, d P<0.05
between high LDL-C/high LDL-P, * P<0.05 between all other groups

Values are presented as mean (standard error). Unless otherwise noted, all models were adjusted for age, race, sex, and baseline body
mass index.

Table 5.21. Significant parameter estimates for the effect of continuous
HDL discordance on exercise induced changes in CVD risk factors
Continuous HDL Discordance Analysis
Parameter
Estimate
P-value
Continuous HDL Discordance
(% difference between HDL-C and HDL-P)
Continuous HDL Discordance
-0.273
<.0001
Cholesterol Measurements, (mg/dL)
-0.515
0.0102
Triglycerides
Lipoprotein Particle Size (nm)
0.003
0.0003
HDL-P size
Lipoprotein particle concentrations (HDL: µmol/L)
0.016
0.0162
HDL-P
0.007
0.0002
Large HDL-P
-2.163
0.0025
Small LDL-P
All models adjusted for age, sex, race, cholesterol medication,
baseline BMI and baseline trait (i.e. adjusting for baseline HDL-P
when assessing change in HDL-P).
Table 5.22. Significant parameter estimates for the effect of
continuous LDL discordance on exercise induced changes
in CVD risk factors
Continuous LDL Discordance Analysis
Parameter
PEstimate
value
Continuous LDL Discordance
(% difference between LDL-C and LDL-P)
Continuous LDL Discordance
-0.4949
<.0001
Cholesterol Measurements, (mg/dL)
LDL-C
-0.2655
0.0097
Anthropometrics
Body Fat (%)
-0.014
0.0311
All models adjusted for age, sex, race, cholesterol
medication, baseline BMI and baseline trait (i.e. adjusting
for baseline body fat when assessing change in body fat).
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CHAPTER 6
OVERALL DISCUSSION
Purpose
The purposes of this dissertation were to: 1) examine the cross-sectional
associations of LDL and HDL discordance with CVD risk factors, 2) investigate the
association of lipoprotein discordance with risk of incident MetS and T2D, and 3) assess
the relationship between baseline discordance status and exercise training induced changes
in CVD risk factors.
Methods
The first study examined the cross-sectional associations of lipoprotein discordance
with CVD risk factor profiles, as well as the relationship between lipoprotein discordance
and risk of T2D or MetS. Participants from the CARDIA study cohort (N=3891). Subjects
participated in six exams from year seven to year thirty of the study. Multiple CVD risk
factors, including a blood lipid panel, were measured at the Year 7 exam with blood
samples additionally being assessed by NMR spectroscopy for lipoprotein subclass
profiles. Each individual’s sex specific discordance status was assessed via both median
based and continuous based discordance as previously described.
The second study examined the association between lipoprotein discordance and
exercise training induced changes in multiple CVD risk factors including continuous
lipoprotein discordance. Two previously completed exercise interventions were used for
this analysis: HERITAGE (N=715) and HART-D (N=214). In HERITAGE, relatively
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healthy adults completed a 20-week progressive exercise intervention using cycle
ergometer exercise, while HART-D included diabetic adults who completed one of four
nine-month interventions: 1) Control, 2) Aerobic Training, 3) Resistance Training or 4)
Aerobic and Resistance Training. Baseline and post intervention measurement of multiple
CVD risk factors were assessed via standardized procedures. Blood samples were taken in
the morning after a 10 (HART-D) or 12 (HERITAGE) hour fast. Samples for HERITAGE
were taken twice at baseline and 24 and 72 hours after the last exercise training session.
Samples for the HART-D study were collected within 48 to 96 hours of the final exercise
bout. Blood samples were assessed for blood lipid panels and NMR lipoproprofile among
other risk factors. Similar to the first study, sex specific discordance status was assessed
via median and continuous based lipoprotein discordance.
Main Findings
Among all studies, more favorable CVD risk factor profiles were found in groups
with higher HDL-C or lower LDL-P regardless of discordance status. High HDL-C groups,
across all studies, displayed higher mean LDL-P size and large HDL-P concentrations.
Lower small LDL-P concentrations were found across all High HDL-C groups except for
females in CARDIA. In HERITAGE and CARDIA, High HDL-C groups displayed lower
BMI, while in HART-D and CARDIA higher mean HDL-P size was seen in these groups.
Within the Low LDL-P groups, lower small LDL-P concentrations were seen across all
studies. In CARDIA and HERITAGE, Low LDL-P groups additionally displayed lower
triglycerides and BMI along with increased mean HDL-P size (except in males in
HERITAGE). Thus, having High HDL-C or Low LDL-P is relatively consistently
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associated with beneficial lipoprotein subclass profiles. Furthermore, outside of HART-D
these phenotypes were associated with lower BMI, regardless of discordance.
In women only in CARDIA, lipoprotein discordance status was associated with risk
of T2D and MetS over 23 years. Higher risk of both outcomes was associated with lower
HDL-C and higher LDL-P concentrations. For example, continuous HDL discordance was
negatively associated with T2D risk, while the Low LDL-C/High LDL-P group was at the
highest risk of MetS among all median based groups. In most models, only lipoprotein
discordance and time varying age were found to be significant predictors of T2D or MetS.
Regarding exercise training induced CVD risk factor changes, lipoprotein
discordance status was found to be primarily predictive of lipoprotein subclass metrics.
HDL discordance was primarily predictive of HDL subclass changes, while LDL
discordance was primarily predictive of LDL subclass changes. Nevertheless, beneficial
within group changes were seen in both exercise training studies for cardiorespiratory
fitness, body fat percentage, and medium LDL-P concentrations, independent of
discordance status.
Conclusions
The studies included in this dissertation are the first to examine lipoprotein
discordance associated risk of either T2D or MetS, as well as the association between
lipoprotein discordance and exercise training induced changes in CVD risk factors.
Consistent favorable risk factor profiles were found in groups with High HDL-C or Low
LDL-P. In women, lipoprotein discordance was a significant risk factor for T2D as well as
MetS. The results of our study highlight the importance of measuring lipoprotein particle
concentrations alongside of their respective cholesterol levels in the prevention and
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management of chronic disease. Although baseline lipoprotein discordance status predicted
differential lipoprotein subclass changes with exercise training, individuals experienced
some level of beneficial change in other CVD risk factors in response to exercise training.
Thus, while lipoprotein discordance may be associated with differential CVD risk factor
profiles, including T2D and MetS, regular exercise remains an advisable lifestyle factor for
the improvement and/or maintenance of risk factors associated with CVD and other chronic
condition
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